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ABSTRACT 
Human embryonic stem cell (hESC) research provides promising prospects for 
the future of regenerative medicine. To fully realize its potentials, we not only need to 
further our understandings toward the molecular mechanisms governing pluripotency and 
differentiation, but also to find new tools to manipulate the processes of directed hESC 
differentiations. One of the best tools for the purpose of probing and manipulating 
biological pathways at the molecular and cellular level is small molecules. High-
throughput screening (HTS) of combinatorial chemical libraries is widely used for the 
search of such bioactive small molecules. My dissertation has focused on using HTS to 
identify novel small molecules that regulate hESC pluripotency and differentiation. Using 
a HTS system based on a novel design, I have screened over 170,000 small molecules 
(Chapter 2), and have studied three hit molecules in detail (Chapters 2, 3, and 4, 
respectively). 
 
The first molecule was named Displurigen (Displg for short) for its ability to 
disrupt hESC pluripotency. Using a biotinylated version of Displg as a probe, I pulled 
down and identified HSPA8 (also known as HSC70, the constitutively expressed member 
of the 70 kd heat-shock protein family) as its biological target, and confirmed this finding 
with both loss-of-function and gain-of-function assays. I showed that HSPA8 helps 
maintain hESC pluripotency by interacting with OCT4 protein and facilitating its binding 
to DNA. This study identified HSPA8 as a novel regulatory component of the hESC 
pluripotency network, and was the first study to demonstrate the direct involvement of a 
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chaperone protein in pluripotency regulation. I describe this work in Chapter 2 of my 
dissertation. 
 
The second molecule was named Mesendogen (MEG for short) for its ability to 
dramatically improve the efficiencies of hESC differentiation towards the mesoderm and 
definitive endoderm (DE) lineages. Cell-replacement therapies require differentiated cells 
of high purity, yet current human pluripotent stem cell differentiation protocols remain to 
be improved for such purposes. I attempted to enhance the commonly used growth factor-
driven mesoderm and DE differentiation protocols using hit molecules acquired from the 
HTS, and identified MEG as a potent enhancer of growth factor-induced mesoderm and 
DE differentiations. Addition of MEG to mesoderm and DE differentiation cultures 
dramatically enhanced both their efficiencies to near homogeneity (≥ 85%). Using target 
identification techniques I identified transient receptor potential cation channel, 
subfamily M, member 6 (TRPM6) as the biological target of MEG. I then showed that 
MEG most likely functions by inhibiting the magnesium import activity of the 
TRPM6/TRPM7 channel complex, the major cellular channel of magnesium import. This 
study describes a robust method for the highly dependable productions of nearly 
homogeneous mesoderm and DE progenitors, and also reveals for the first time that 
TRPM6/TRPM7 channel activity and magnesium homeostasis may be involved in the 
regulation of early mesoderm and definitive endoderm specifications. This work is 
described in Chapter 3 of my dissertation.  
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The third molecule was named Lymphgen 1 for its activity in inducing the self-
organization of a putative primitive lymphatic plexus-like structure, in the shape of a 
balloon, out of 2-D hESC cultures and without the addition of any growth factors. Its 
structural analog, Lymphgen 2, was analyzed in parallel. Recently, several studies 
reported self-organization events of hESCs that give rise to three dimensional (3-D) 
organoid structures, all of which required pre-designed programs of external guidance 
such as growth factors during their differentiations. Inspired by these findings, I 
hypothesized that by applying an appropriate stimulus such as a small molecule inhibitor 
at the onset of differentiation, it may be possible to trigger an intrinsic developmental 
program embedded in hESCs that does not require any external guidance to progress into 
a self-organizing structure. To find such a stimulus, I systemically examined my hit 
compounds for their abilities to trigger self-organizing events, and found compounds 
Lymphgen 1 and 2 (collectively referred to as Lymphgens hereafter) that trigger an 
unguided and spontaneous self-organizing event which gives rise to a balloon-like 
organoid structure. Gene expression analyses, functional assays, and morphological 
studies demonstrated that this self-organizing event may have recapitulated the in vivo 
human lymphatic morphogenesis program. Using this system, I unveiled the unguided 
emergence of a DiI-Ac-LDL+VE-cadherin+CD31+CD34+KDR+CD43- endothelial 
progenitor population, and identified a previously unknown VEGFR3+ progenitor 
population which may be responsible for human embryonic lymphatic development. This 
system provides a rare opportunity to visualize a truly spontaneous human developmental 
program in vitro. This work is described in Chapter 4 of my dissertation.  
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In summary, my dissertation described the development of a human pluripotent 
stem cell-based HTS platform that was built upon a unique and novel approach which 
was eventually proven to be highly effective. It also described the discoveries and 
detailed studies of three hit molecules found in the HTS. Through comprehensive studies 
of these molecules, I unveiled novel regulatory mechanisms at the molecular level that 
govern hESC pluripotency and differentiation. Moreover, using these small molecules as 
tools, I significantly improved upon current protocols for both guided lineage-specific 
differentiations and spontaneous organoid self-organizations of hESCs. My thesis work 
has been dedicated to advancing the field of hESC research through the use of chemical 
biology. 
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CHAPTER 1: GENERAL INTRODUCTION 
 
Background and Significance of Human Embryonic Stem Cells 
Human embryonic stem cells (hESCs) are pluripotent stem cells derived from the 
inner cell mass of preimplantation human blastocysts (Thomson et al., 1998). Two major 
characteristics of hESCs are its ability to proliferate indefinitely in culture while 
maintaining an un-transformed (karyotypically normal) state (self-renewal), and its 
ability to differentiate into tissues of all three embryonic germ layers including mesoderm, 
endoderm, and ectoderm (pluripotency).  
 
Originally the undifferentiated growth of hESCs was supported by the presence of 
mouse embryonic fibroblasts (MEFs) as feeder cells (Thomson et al., 1998). A feeder-
free condition was later developed in which hESCs were cultured on Matrigel coated 
surfaces in medium conditioned by MEFs (Xu et al., 2001), followed by the discovery of 
a feeder-independent culture system including the use of a medium with a fully defined 
chemical composition (Ludwig et al., 2006). In all the above culture methods, 
undifferentiated hESCs typically grow as colonies with tightly packed cells and well-
defined boarders. Differentiated cultures, on the other hand, usually display colonies and 
cells that lack the compact morphologies described above (Thomson et al., 1998).   
 
From a clinical perspective, currently hESCs and human induced pluripotent stem 
cells (hiPSCs) and their differentiated progenies provide the best hopes for treating 
various diseases that require tissue replacement therapies such as type 1 diabetes, heart 
attack, stroke, neurodegenerative diseases, spinal cord injury, and so on. The prospect of 
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using hESCs and hiPSCs to generate functional organs for transplantation could also be 
made reality in the future.  
 
From a basic research perspective, hESCs represent an easily accessible 
experimental system for the study of early human development, as availability of human 
embryos and fetuses are severely limited due to ethical reasons. Disease-specific hESCs 
and hiPSCs are now widely used as models for human genetic and developmental 
disorders (Wu and Hothedlinger, 2011). 
 
Molecular mechanisms governing hESC pluripotency and differentiation 
External factors and internal regulatory networks work together to maintain hESC 
pluripotency in the culture system. External pluripotency maintaining factors include cell 
culture substrates such as Matrigel and MEF feeders, and medium components such as 
basic nutrients and growth factors (Ludwig et al., 2006; Thomson et al., 1998). The 
internal pluripotency regulatory factors known to date are mostly transcription factors 
and epigenetic factors. Transcription factors OCT4, NANOG, and SOX2 are thought to 
form a core regulatory circuit which maintains hESC pluripotency (Boyer et al., 2005). 
Many other transcription factors form a supplementary network which connects to and 
supports the integrity of the core regulatory circuit (Ng and Surani, 2011). As pluripotent 
hESCs possess a distinct epigenetic state compared to differentiated cell types (Gifford et 
al., 2013), not surprisingly, epigenetic regulating factors such as chromatin remodeling 
complexes, DNA modification factors, and histone modification factors are also crucial 
to the maintenance of pluripotency (Hu and Rosenfeld, 2012). My research has unveiled 
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a member of the heat-shock protein family as a novel pluripotency regulatory factor, 
which is detailed in Chapter 2 of this dissertation. 
 
Disruption of the pluripotency maintenance network leads to differentiation. 
Disruption of pluripotency by itself generally does not lead to lineage specific 
differentiations; rather, loss of pluripotency followed by an un-guided differentiation 
protocol such as the embryoid body (EB) method usually leads to the random production 
of multiple types of differentiated progenies at the same time. To produce specific types 
of differentiated cells, the differentiation processes must be precisely guided. This is 
generally achieved by the supplementation of external factors or direct manipulation of 
internal factors that regulate specific differentiation pathways. Currently the majority of 
regulatory pathways targeted for directed differentiation of hESCs have been discovered 
from developmental biology studies using animal models.  
 
Small molecules as tools for hESC research 
The term “small molecules” commonly refers to organic compounds with 
molecular weights lower than 900 Daltons (Macielag, 2012), as 900 Daltons is believed 
to be the upper molecular weight cutoff for a molecule to be able to rapidly diffuse across 
cell membranes. In the field of basic and clinical biomedical research, the term “small 
molecules” usually specifically refers to molecules with the capabilities of regulating 
biological processes. A more restricted use of the term refers only to molecules that binds 
to specific biopolymers, such as proteins or nucleic acids, and exert their biological 
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functions through these interactions. Most of the currently available drugs are small 
molecules (Macielag, 2012).  
 
Advantages of applying small molecules for biological studies include their high 
potency, robustness, and ease of application. In general, nano-molar to micro-molar 
concentrations of a small molecule is enough to effectively and specifically inhibit its 
biological target(s). Small molecules can be readily applied for clinical use as drugs 
without the need for extensive optimizations of clinical procedures.  
 
One disadvantage is that some small molecules may have more than one 
biological target, which can lead to misinterpretation of experimental results; other 
experimental methods must be used in parallel to confirm results acquired using small 
molecules. Another disadvantage is that we don't always know the biological target of a 
given small molecule. Overcoming this problem requires searching for their targets using 
target ID techniques to help us better understand the mechanism of action (MoA) of those 
molecules.  
 
Small molecules have been successfully used in early studies to help maintain 
hESC pluripotency and to elucidate basic signaling requirements of hESC pluripotency 
(Gonzalez et al., 2011b; Kumagai et al., 2013; Li et al., 2007; Vallier et al., 2005; Xu et 
al., 2010b). An early example was the study reported by Austin Smith and colleagues, 
using the combination of 3 small molecules (3i) to maintain a ground state of mESC in 
culture that does not rely on the addition of any growth factors (Ying et al., 2008); similar 
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results have been reported in hESCs (Tsutsui et al., 2011). More recently, small 
molecules have been extensively applied to the studies of prime versus naïve 
pluripotency (Chan et al., 2013; Chou et al., 2008; Hanna et al., 2010; Ware et al., 2009; 
Zhou et al., 2010a) and induced pluripotent stem cell (iPSC) derivations (Esteban et al., 
2009; Huangfu et al., 2008; Li et al., 2012; Li et al., 2009; Lin et al., 2009; Maherali and 
Hochedlinger, 2009; Mali et al., 2010; Moschidou et al., 2012; Wang et al., 2011; Wei et 
al., 2014; Yu et al., 2014; Yuan et al., 2011; Zhu et al., 2010). 
 
Small molecules were also widely used for the study of PSC lineage-specific 
differentiation. BMP pathway inhibitors have been used as central components of neural 
ectoderm differentiation. Meanwhile a variety of small molecule inhibitors have been 
discovered that facilitates either general or  sublineage-specific mesoderm and endoderm 
differentiations, such as IDE1/2 for definitive endoderm differentiation (Borowiak et al., 
2009b) (although a later report challenged the effectiveness of this molecule (Tahamtani 
et al., 2013)), (-)-indolactam V for pancreatic lineage differentiation (Chen et al., 2009), 
GSK3b inhibitors for cardiomyocyte differentiation (Gonzalez et al., 2011a; Lian et al., 
2012), and SB431542 for differentiation into mesenchymal progenitors (Chen et al., 2012; 
Mahmood et al., 2010). 
 
To expand our current understandings of hESC pluripotency and differentiation, 
there is a dire need for new tools that can probe the hESC system in novel angles in the 
hope that previously unknown molecular mechanisms that govern pluripotency and 
differentiation can be revealed. It is also crucial to develop improved methods of lineage 
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specific differentiation for hESCs in order to achieve its full potential in regenerative 
medicine. Small molecules represent an ideal candidate tool for probing the molecular 
pathways of pluripotency and differentiation, and for improving the current 
differentiation methods, as will be discussed in the following sections.  
 
Goals of my dissertation 
My dissertation research has been dedicated to advancing hESC research using 
chemical biology. My work has been focused on: 1) using high-throughput screening 
(HTS) to find novel chemical compounds that regulates hESC pluripotency and 
differentiation; 2) finding the biological targets of those molecules using target 
identification (target ID) techniques to further our understandings toward the molecular 
mechanisms of hESC pluripotency and differentiation; and 3) deriving new and improved 
methods for hESC fate manipulation using the hit compounds. 
 
Using high-throughput screening to discover novel small molecules that modulate hESC 
fate 
The first goal of my dissertation was to use high-throughput screening (HTS) to 
identify novel chemical compounds that can be used to manipulate hESC fate. HTS is a 
drug or small molecule discovery method widely used in the field of biomedical sciences 
and the pharmaceutical industry. By using automated machinery and data processing, 
HTS allows researchers to conduct tests of a large number of chemicals in a short time 
frame to rapidly identify bioactive compounds. HTSs give rise to "hit" compounds. 
Validated hit compounds are generally referred to as "lead" compounds, meaning that 
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these compounds have confirmed biological activities but may require further 
modification and optimization of their structures to enhance their targeting efficiencies. 
 
HTS searches bioactive small molecules from compound "libraries". A compound 
library may consist of compounds acquired from combinatorial chemistry (these libraries 
are therefore referred to as "combinatorial libraries"), natural products, collections of 
small molecules with known biological functions, compounds synthesized based on 
rational drug designs, or mixtures of the above mentioned sources.   
 
Multiple drug candidates have been discovered through the use of HTS. Some 
examples of such discovery are the chemokine receptor antagonist maraviroc 
(Selzentry/Celsentri; Pfizer) and the thrombopoietin receptor agonist eltrombopag 
(Promacta/Revolade; GlaxoSmithKline) (Macarron et al., 2011).  
 
HTSs have also been used for the discovery of novel small molecule compounds 
that regulate pluripotent stem cell (PSC) fate. Candidate platforms (in this case cells) that 
can be used for screening pluripotency regulators are the pluripotent stem cell lines, 
including mouse embryonic stem cells (mESCs), mouse embryonal carcinoma cells 
(mECCs), human embryonic stem cells (hESCs), and human embryonal carcinoma cells 
(hECCs). The more recent advances in the field of induced pluripotent stem cell (iPSC) 
technology made possible to use human iPSCs (hiPSCs) as the screening platforms as 
well. Disease-specific hiPSCs are especially useful for selecting drug candidates for the 
treatment of those diseases.  
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Earlier attempts of using HTS for the search of pluripotency regulators mainly 
focused on using mouse embryonic stem cells (mESCs) and mouse embryonal carcinoma 
cells (mECCs) as screening platforms. Compared to hESCs, mESCs and mECCs were 
easier to handle, cheaper to maintain, and more robust at staying in a pluripotent state. An 
example of compounds found in these studies was SC1, a small molecule that helped 
maintain mESC pluripotency, discovered in a mESC based screening by plating mESCs 
under differentiation conditions and selecting for small molecules that helped maintain 
pluripotency (Chen et al., 2006b). Another example was the compound TWS119, a small 
molecule that induced neuronal differentiation of mESCs, discovered using a HTS 
platform based on the use of mEC cell line P19 (Ding et al., 2003). 
 
More recently several groups have adopted hESCs as HTS platforms. Desbordes 
et al. screened 2880 compounds using H9 hESCs as the screening platform and OCT4 
immunostaining as readout for compounds that disrupt pluripotency (Desbordes et al., 
2008). Xu et al. used HUES9 hESCs as their screening platform and ALP staining as 
readout for compounds that maintained cell survival and pluripotency (Xu et al., 2010b).  
 
Despite these efforts, the problems of high cost and high levels of experimental 
variations that are associated with using hESCs as a HTS screening platform still remain. 
Researchers are now searching for ways to bypass the flaws of hESC-based HTSs. A 
recent study by Caron et al. attempted to solve this problem by generating a hESC line 
that's genetically abnormal and have characteristics that make it suitable for HTS. They 
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have yet to perform an actual HTS using this cell line (Caron et al., 2013). To date, there 
have been no reports of using human embryonal carcinoma cells (hECCs) as HTS 
platforms.  
 
To overcome the limitations of using hESC for HTS, I attempted a new approach 
by developing a NTERA-2 hECC-based screening system for HTS. Human embryonal 
carcinoma cells (hECCs) are pluripotent stem cells derived from human teratocarcinomas 
and are considered to be the malignant counterparts of hESCs. Compared to hESCs, 
hECCs usually possess abnormal karyotypes and characteristics of transformed cells, 
meaning they are in general more robust at maintaining a pluripotent state in culture, 
require less care for routine maintenance, and can be maintained in simple and cheaper 
culture mediums without the addition of expensive growth factors. Consequently, results 
acquired from studies using hECCs were believed to be more stable and readily 
reproducible; in fact, a hECC line named 2102Ep was recommended to be included as a 
"reference cell line" in all PSC-related studies so that results acquired from different PSC 
lines maintained by different labs could be compared (Josephson et al., 2007).   
 
I chose to use the hECC line NTERA-2 to construct my HTS platform. NTERA-2 
is a clonal subline of TERA-2, one of the first established hECC lines (Andrews et al., 
1984). NTERA-2 cells are able to differentiate into all three germ layers in vivo in the 
form of teratocarcinomas. In culture these cells differentiate in response to several 
differentiation inducers, most notably retinoic acid (Andrews, 1984), hexamethylene bis-
acetamide (HMBA) (Andrews et al., 1986; Andrews et al., 1990), and bone 
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morphogenetic protein-7 (Andrews et al., 1994). These agents also induce differentiation 
of hESCs (Draper et al., 2002; Xu et al., 2002; zur Nieden et al., 2005). These properties 
demonstrate that NTERA-2 cells share similar molecular mechanisms underlying their 
pluripotent state as compared to hESCs. 
 
I then constructed a NTERA-2 reporter cell line by stable integration of an 
enhanced green fluorescence protein (EGFP) reporter gene driven by a 4 kb OCT4 
promoter (Gerrard et al., 2005). Using this system, I successfully screened over 171,077 
small molecule compounds. Details of this screen are described in Chapter 2 of my 
dissertation. 
 
Elucidating biological targets of the hit compounds acquired from HTS using target 
identification techniques 
The second goal of my dissertation was to find the biological targets of the hit 
molecules using target identification (target ID) techniques, in the hopes of identifying 
biological pathways affected by the hit molecules, and to possibly discover novel 
molecular mechanisms governing hESC pluripotency and differentiation. Target ID refers 
to the process of identifying biological targets (most often being proteins) of bioactive 
small molecules using affinity reagents and pull down assays. The concept of target ID is 
built upon the assumption that the phenotype elicited by a small molecule arises from the 
cellular consequence of a direct interaction between the small molecule and its target 
protein(s). Many target ID strategies are available and several have been applied to my 
thesis study.  
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One of the most widely applied target ID approach is the use of a chemically 
modified version of a hit compound to fish out its binding target(s). Biotinylated versions 
of hit compounds are frequently used as probes for this type of approach. After 
incubation with live cell culture or cell lysates, biotinylated hit compounds, together with 
its binding protein(s), are immobilized by streptavidin, NeutrAvidin, or avidin beads. 
Eluted binding protein(s) are separated by gel electrophoresis and visualized by silver 
staining. Protein bands of interest are analyzed by mass spectrometry (Leslie and 
Hergenrother, 2008). A successful demonstration of this method is described in Chapter 2 
of my dissertation.  
 
Protein arrays have also been used to identify binding partners of a small 
molecule in vitro. Using this method, labeled hit molecules are incubated with chips 
coated by recombinant proteins at defined positions (dots), and scanned for signals. Dots 
with high signals are identified as candidate targets. An advantage of this method is that 
small molecules can be labeled using a wide variety of tags including radio-isotopes, 
fluorescent molecules, biotin, and so on. The power of this method is mainly limited by 
its in vitro binding environment and the number of recombinant proteins available on the 
chip. This type of protein chips is commercially available, such as the Invitrogen 
Proteome Array. 
 
A commercially available screening service named "KINOMEscan" provided by 
DiscoveRx takes advantage of ligand competition to identify possible kinase targets of a 
small molecule. The basic design of this screen includes binding of a library of DNA-
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tagged recombinant kinases to their ligands linked to a solid support. When a small 
molecule of interest binds to a certain kinase, it competes with the ligand of that kinase 
either by direct competition at the ligand biding site or by binding to other parts of the 
kinase and induce conformational change of the protein, thus releasing this kinase from 
the solid support. Kinases released from the ligands are collected and identified by PCR 
using their DNA tags as templates. A demonstration of this method is described in 
Chapter 3 of my dissertation.  
  
After target ID identifies the protein target(s), several techniques can be used to 
further validate this interaction. These include methods that directly measure the binding 
of small molecules to proteins such as surface plasma resonance (SPR), and methods that 
measure the functional or biochemical consequences of compound-protein interactions 
such as a method named DARTS which detects conformational changes of a target 
protein (Lomenick et al., 2009; Lomenick et al., 2011), or ATPase assays and kinase 
assays which measure changes in the enzymatic activities of the target protein. These 
validation methods can only be applied when a candidate target protein is already 
identified, and cannot be used for exploratory purposes.  
 
Enhancing hESC differentiation toward defined lineages using small molecules 
The third goal of my dissertation was to derive new and improved methods for 
hESC fate manipulation using hit compounds acquired from the HTS. To realize this goal, 
I first searched if any of the hit molecules from the screening can guide or enhance hESC 
differentiation toward a defined lineage. 
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The major challenge of hESC-based regenerative medicine is to develop methods 
that can produce a large quantity of differentiated progenies that consist of a highly 
homogeneous (in terms of cellular identities and functions) disease-relevant cell type. 
Earlier attempts at hESC differentiation generally adopted a three dimensional (3-D) 
differentiation culture system. In this method, hESCs aggregate in suspension culture and 
form 3-D spheres called embryoid bodies (EBs). Embryoid bodies then undergo 
spontaneous differentiation and form cyst-like 3-D spheres with differentiated internal 
tissues consisting of cells with different identities that correspond to progenies of all three 
germ layers. The EB differentiation method was originally derived from mouse ES cell 
research, in which EBs were formed by aggregating single cells in a drop of medium 
hanging in the lid of a culture vessel and termed "hanging drop" method. However, in the 
earliest examples of hESC-based EB differentiation, instead of using the hanging drop 
method, researchers generated EBs from individual hESC colonies by lifting them as a 
whole from the cultures (Itskovitz-Eldor et al., 2000b). This was because hESCs survive 
poorly as single cells due to anoikis (apoptosis induced by loss of cell-cell contact). EBs 
obtained via this method varied greatly in size, causing experimental variations. This 
problem was later solved by the addition of ROCK inhibitor Y-27632 as an anoikis 
inhibitor to improve hESC survival. With the addition of Y-27632 it was then possible to 
use either the hanging drop method or specially designed micro-well culture plates to 
aggregate EBs from single hESCs, giving rise to well controlled, uniformly sized EBs.  
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However, a disadvantage of this differentiation system is that cells at the outer 
surface of a EB can limit the contact of differentiation inducing factors presented in the 
culture medium to cells on the inside of the EB. Due to this reason homogeneous 
differentiation within EBs can be very difficult to achieve. Thus more recent protocols 
often enrich target differentiation lineages by replating EBs into selective two 
dimensional (2-D) culture systems (Levenberg et al., 2002; Zhang et al., 2001).  
 
A better way to produce highly homogeneous differentiated progenies may be to 
keep the differentiation cultures two-dimensional throughout the differentiation process. 
The major benefit of a 2-D culture system is that it keeps all cells exposed to the same 
open environment and thus provides all cells with equal access to the differentiation 
inducing factors in the medium, creating a differentiation condition that is easy to 
monitor and guide. Therefore current methods of differentiation generally adopt a 2-D 
culture system, within which researchers can easily apply a step-wise induction protocol 
and guide the differentiation process through timely addition of different growth-factor 
combinations during the course of differentiation (Cai et al., 2007; Chen et al., 2009; 
D'Amour et al., 2006; Perrier et al., 2004; Wang et al., 2007; Wong et al., 2012).  
 
I have modified existing protocols and established consistent methods for growth 
factor-induced 2-D differentiations of early human mesoderm and definitive endoderm 
(DE) progenitors. I tested hit compounds acquired from the HTS (Chapter 2) and found 
MEG, a small molecule that enhanced both mesoderm and endoderm differentiation 
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efficiencies to near homogeneity (≥ 85%). Details of this discovery are described in 
Chapter 3 of my dissertation. 
 
Deriving 3-D self-organizing organoids using small molecules 
Also to achieve the third goal of my thesis study, I explored the possibility of 
using hit compounds acquired from the HTS (Chapter 2) to trigger an intrinsic, self-
organizing differentiation process that mimics an innate human developmental program 
from hESCs. The term "self-organization" refers to the process of spontaneous formation 
of a highly ordered structure from nonprepatterned elements (Sasai, 2013). 
 
Probably one of the biggest challenges faced by the research of early human 
development is the lack of an easily accessible experimental model, as the availability of 
human embryos or fetuses are extremely limited. The establishment of the first hESC line 
in 1998 by James Thomson (Thomson et al., 1998) offered a possible solution to this 
problem. If we can manipulate hESCs into undergoing an in vitro differentiation program 
that mimic an in vivo human developmental processes such as organ-formation, 
researchers will be able to confirm the current knowledge of human development that 
was largely acquired through studies using animal models, and to possibly identify novel 
developmental pathways that are unique to human development. Furthermore, the 
combined use of such systems with genetically engineered hESCs or disease-specific 
hiPSCs will provide models for the study of human genetic or developmental disorders, 
providing the hope to eventually develop treatments for these conditions. The 
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development of such differentiation systems remained an elusive goal until 10 years after 
the establishment of the first hESC line.  
 
In 2008 researchers in Yoshiki Sasai’s group reported the generation of the first 
self-organizing cortical tissue structures from mouse and human ESCs (Eiraku et al., 
2008). Using a 3-D EB culture system developed in their lab named serum-free culture of 
embryoid body-like aggregates (SFEB), apico-basally polarized cortical tissues were 
generated. In this system, both spatial and temporal specifications of the cortical organoid 
could be regulated using experimental methods.  The same group later developed 
methods for the generation of self-organizing optic-cups from mESCs (Eiraku et al., 2011) 
and hESCs (Nakano et al., 2012), self-forming isthmic organizertissues from mESCs 
(Muguruma et al., 2010), and self-forming anterior pituitary from mESCs (Suga et al., 
2011), using similar 3-D EB culturing approaches.  
 
These reports spawn a series of studies using similar or modified 3-D EB culture 
systems, or combinations of 2-D and 3-D culture systems, to trigger various self-
organizing differentiation events using mESCs or hESCs. Examples include the self-
formations of organoids resembling thyroid (Antonica et al., 2012), gut (Cao et al., 2011; 
Ueda et al., 2010), and pancreatic islets (Saito et al., 2011; Wang and Ye, 2009).  
 
Another unique approach has been reported individually by two groups that relied 
solely on 2-D culture systems for organoid formation. Researchers in James Wells’s 
group reported the growth of gut-like organoids out of a 2-D hPSC culture system 
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directed by a series of growth factor combinations (McCracken et al., 2014; Spence et al., 
2011; Wells and Spence, 2014). Melissa Little’s group also reported budding of 
embryonic kidney-like structures from 2-D hESC cultures (Takasato et al., 2014). A 
unique characteristic of this approach is that the 3-D structures self-organized through the 
process of "budding" or “sprouting” out of a 2-D surface. Similar budding or sprouting 
processes are present throughout development and are crucial to a variety of 
organogenesis events.  
 
However, all methods published to date required the guidance of externally 
applied growth-factor combinations. Hoping to establish an organoid self-organization 
protocol dictated entirely by internal programs of the cells rather than having to rely on 
outside stimulus (Sasai, 2013), I hypothesized that by applying an appropriate stimuli, it 
may be possible to trigger an intrinsic developmental program of hESCs in culture, and 
thus create an organoid self-formation protocol that does not require any external 
guidance. In other words, by giving an initial "push" to the hESC system, we may be able 
to jump-start a developmental program that can, all by itself, run through its course in 
culture without interference. I demonstrate the induction of a self-organizing organoid-
formation event by small molecules in Chapter 4 of my dissertation. 
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CHAPTER 2: A CHEMICAL BIOLOGY STUDY OF HUMAN PLURIPOTENT 
STEM CELLS UNVEILS HSPA8 AS A KEY REGULATOR OF PLURIPOTENCY 
 
Abstract 
Chemical biology methods such as high throughput screening (HTS) and affinity-
based target identification can be used to probe biological systems on a 
biomacromolecule level, thus providing valuable insights into the molecular mechanisms 
of those systems. Here, by establishing an innovative human embryonal carcinoma cell-
based HTS platform, I screened 171,077 small molecules for regulators of pluripotency, 
and identified a novel small molecule Displurigen which potently disrupts hESC 
pluripotency by targeting heat shock 70kDa protein 8 (HSPA8), the constitutively 
expressed member of the 70kDa heat-shock protein family, as elucidated using affinity-
based target identification techniques and confirmed by loss-of-function and gain-of-
function assays. I demonstrated that HSPA8 maintains pluripotency by binding to the 
master pluripotency regulator OCT4 and facilitating its DNA-binding activity. This study 
uncovers a novel function of HSPA8 in the maintenance of hESC pluripotency, and is the 
first report demonstrating the direct involvement of a chaperone protein in pluripotency 
regulation.   
 
Introduction 
Pluripotency regulators OCT4, NANOG, and SOX2 form a core transcription 
regulatory network through auto- and reciprocal-activations at the transcription level, 
which is believed to be responsible for the maintenance of human embryonic stem cell 
(hESC) pluripotency (Boyer et al., 2005). At the same time, multiple protein factors 
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belonging to a diversity of functional categories such as transcription factors, epigenetic 
factors, and signaling components work cooperatively to form an expanded pluripotency 
factor network which supports the core pluripotency network (Boyer et al., 2005). In 
contrast to the well-defined core network, our knowledge toward this expanded 
pluripotency network, including its components, the interactions between these 
components, and the mechanism-of-interaction between the expanded network and the 
core network, remains insufficient. 
 
Bioactive small molecules have been applied to the field of hESC research with 
success. Many such studies applied small molecules as modulators of lineage-specific 
differentiations (Borowiak et al., 2009b; Chen et al., 2009; Chen et al., 2012; Gonzalez et 
al., 2011a; Lian et al., 2012; Mahmood et al., 2010); other studies exploited small 
molecules as chemical probes to uncover novel molecular mechanisms underlying hESC 
pluripotency or differentiation (Chen et al., 2006a; Xu et al., 2010a; Zhu et al., 2009). 
High-throughput screenings (HTS) were usually conducted for the search of such 
molecules. If the mechanism-of-action was unknown for a given molecule, affinity-based 
target identification methods can be used to identify its biological target(s). These studies 
have been used to identify novel protein factors and to unveil previously unknown 
molecular mechanisms that regulate hESC fate determination (Xu et al., 2008). 
 
Cell-based HTSs require the use of stable and robust cellular platforms. However, 
hESC cultures are highly sensitive to the environment and are prone to spontaneous 
differentiation, thus not ideal for HTS applications (Caron et al., 2013). To solve this 
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problem, I chose to explore an alternative source of pluripotent stem cells, human 
embryonal carcinoma cells (hECCs), as a platform for HTS. hECCs are pluripotent stem 
cells derived from human teratocarcinomas and are considered to be the malignant 
counterparts of hESCs. The molecular regulatory mechanism of hECC pluripotency has 
been shown to mimic that of hESCs (Josephson et al., 2007). Due to their cancerous 
nature, hECCs are significantly less prone to spontaneous differentiation and require a 
much less demanding culturing condition than hESCs. Consequently, results acquired 
from studies using hECCs have been proven to be more stable and readily reproducible 
compared to hESCs (Josephson et al., 2007). 
 
Based on the novel concept of hECC-based HTS, I established a pluripotency 
reporter system using the hECC line NTERA-2. Using this system, I conducted a large-
scale chemical screening, and found 122 small molecules that disrupt hESC pluripotency. 
One of these molecules, which I named Displurigen, potently disrupts hESC pluripotency 
by targeting heat shock 70kDa protein 8 (HSPA8; the constitutively expressed member of 
the 70 kd heat-shock protein family), as discovered using affinity-based target 
identification methods and through functional validations. I demonstrated that HSPA8 
helps maintain pluripotency by direct-binding to the OCT4 protein and facilitating OCT4 
binding to DNA. 
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Results 
Establishment of a NTERA-2 cell-based pluripotency reporter system 
To avoid high experimental variations associated with hESC-based HTS 
platforms, I established a HTS plarform using the hECC line NTERA-2. NTERA-2 is a 
clonal subline of TERA-2, one of the first established hECC lines (Andrews et al., 1984). 
NTERA-2 cells are able to differentiate into all three germ layers in vivo in the form of 
teratocarcinomas. In culture these cells differentiate in response to several inducers of 
differentiation, most notably retinoic acid (RA) (Andrews, 1984), hexamethylene bis-
acetamide (HMBA) (Andrews et al., 1986; Andrews et al., 1990), and bone 
morphogenetic protein-7 (Andrews et al., 1994); these agents also induce differentiation 
of hESCs (Draper et al., 2002; Xu et al., 2002; zur Nieden et al., 2005). Furthermore, 
basic fibroblast growth factor (bFGF) helps maintain the pluripotent state of both 
NTERA-2 cells and hESCs (Andrews et al., 1984; Thomson et al., 1998). The similarities 
in their responses toward external factors indicate that NTERA-2 cells and hESCs have 
very similar molecular mechanisms governing their respective pluripotent states.  
 
An NTERA-2 cell-based reporter cell line was constructed by stable-integration 
of an enhanced green fluorescence protein (EGFP) reporter gene driven by a 4 kb OCT4 
promoter (Gerrard et al., 2005). EGFP positive cells were selected by flow cytometry 
after drug selection. The selected stable cell line nearly homogeneously expressed EGFP 
and maintained this expression after multiple (over 20) rounds of passaging (Figure 2.1A). 
This reporter line is hereafter referred to as NTERA-2-OP4k, with "OP4k" referring to 
the 4 kb OCT4 promoter. To test the response of this reporter system to known external 
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regulators of pluripotency, NTERA-2-OP4k cells were cultured at low density and 
incubated with known inhibitors of pluripotency including RA and HMBA, and with an 
enhancer of pluripotency, bFGF, for 6 to 7 days. ROCK inhibitor Y-27632 was also 
tested as a cell survival enhancer (Watanabe et al., 2007). RA and HMBA dramatically 
reduced cellular EGFP signal, as shown by fluorescent imaging and FACS analysis 
(Figures 2.1B and 2.1C); this was accompanied by a dramatic downregulation of the 
endogenous protein expression of OCT4, shown by Western blotting (Figure 2.1D). On 
the other hand, in bFGF- and Y-27632-treated cells, the EGFP expressions and the 
endogenous expressions of OCT4 remained largely un-altered, as compared to the DMSO 
control (Figures 2.1B-2.1D). These results demonstrate that the EGFP expression of 
NTERA-2-OP4k reporter cells is regulated by known regulators of pluripotency in the 
same way as does the expression of the endogenous OCT4, and indicate that the OCT4-
EGFP reporter signal faithfully reflects the endogenous expression of OCT4 and the 
pluripotency state of the cells. 
 
NTERA-2-OP4k cell-based HTS identified small molecule regulators of pluripotecy 
Before applying the NTERA-2-OP4k reporter system to HTS, I first verified 
whether the responses of the OCT4-EGFP reporter could be accurately measured under a 
HTS condition. For this test, NTERA2-OP4k cells were seeded at low densities (0.1 – 
0.25 × 105 cells/cm2) in 96-well plates. Pluripotency and survival regulators including 
RA, HMBA, bFGF, and Y-27632 were added immediately following cell plating. Cells 
were incubated for 6 to 7 days without medium change, and then scanned for EGFP 
signal using a fluorescent plate reader. As a result, cells treated with pluripotency 
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inhibitors RA and HMBA showed significantly decreased EGFP signals, while bFGF- 
and Y-27632-treated cells maintained high levels of EGFP signals, as compared to the 
DMSO control (Figure 2.2A). This result is consistent with previous results obtained by 
fluorescent imaging and FACS analysis under non-HTS settings (Figures 2.1B and 2.1C), 
thus confirming the validity of using NTERA-2-OP4k as a pluripotency reporter line for 
HTS.  
 
A total of 171,077 small molecules with diverse chemical structures were 
screened using the NTERA-2-OP4k reporter cell-based platform. These molecules were 
hosted by the UIUC HTS facility in 4 chemical libraries. For the screen, NTERA-2-OP4k 
cells were seeded at low densities in 96- or 384-well plates and incubated with screening 
compounds and DMSO controls (included in all screening plates) added using pin-tools 
immediately after seeding, at final concentrations described in Materials and Methods. 
Cells were kept in a 37°C incubator for 6 to 7 days without medium change, and then 
scanned for EGFP signal intensities using a fluorescent plate reader. Wells with EGFP 
intensities lower than 70% of the average EGFP intensity of the DMSO controls (average 
level of background signals subtracted before comparison) in the same plates were 
identified as candidate hits.  
 
I expect two types of compounds to produce false positives by reducing EGFP 
signal intensities in the treated wells without inducing cellular differentiation. Those 
include cytotoxic or apoptosis-inducing compounds that caused cell death (Figure 2.2B: 
"cell death"), and compounds that inhibited cell proliferation (Figure 2.2B: "reduced 
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growth"). A compound that fell into either of the two categories would have reduced the 
total number of cells in the treated well and thus able to lower its EGFP signal intensity 
without actually disrupting the pluripotent status of cells in that well. A real hit 
compound, however, would have downregulated EGFP expression on a cellular level 
(Figure 2.2B: "primary hits"). To distinguish between the actual hit compounds and 
compounds that generated false positive signals, I inspected all wells that showed 
significant EGFP signal reduction under a fluorescent microscope immediately after the 
fluorescent plate reader scan. Based on the criteria descried above, I identified the wells 
in which EGFP signals were reduced on a cellular level as true primary hits. As a result, 
while 2865 (1.7% of all compounds screened) compounds were identified as candidate 
hits based on their reduced EGFP signals, only 214 (0.13% of all compounds screened) of 
those compounds were verified as primary hits (Figure 2.2C).  
 
I then validated the pluripotency-disruption activities of the primary hits in hESCs. 
Primary hit compounds were cherry-picked from the original screening plates and applied 
to hESCs at concentrations close to their concentrations used in the HTS (Materials and 
Methods). H1 and H9 hESCs were seeded as colonies and incubated with the compounds 
under the feeder-independent pluripotency culture condition (Materials and Methods) for 
4 - 6 days; medium was changed and compounds replenished every day or every other 
day. Cultures were monitored every day for loss of compact colony morphologies as 
signs of differentiation. Compounds that failed to disrupt hESC colony integrity at the 
concentrations tested were examined again at 5 - 10 fold increased concentrations under 
the same condition. Finally, a total of 122 compounds were found to disrupt hESC colony 
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integrity (Figure 2.2C). These compounds are hereafter referred to as the hESC-verified 
hits, or verified hits. 
 
From the verified hits, I selected the ones that showed strong potencies (effective 
at relatively low concentrations) at inducing hESC differentiation, acquired those 
compounds in-bulk from commercial sources, and further verified their activities at the 
molecular level. Various techniques including Western blotting, qPCR, immunostaining, 
and FACS analysis were used to examine changes in the expression of pluripotency 
markers upon treatments of those compounds. Out of the 30-plus compounds tested in 
detail, 29 compounds efficiently downregulated the expressions of pluripotency markers 
in H1 and H9 hESCs (data not shown). 
 
Compound Displurigen potently disrupts hESC pluripotency 
Among those 29 compounds, compound NSC375009 from the NCI library was 
one of the most potent. I hereafter refer to this compound as Displurigen (Displg for short) 
for its property as a "reagent that disrupts pluripotency" (Figure 2.3A). When applied at 5 
M for 6 days, the colony integrity of hESCs was completely disrupted, as evidenced by 
cells within the colonies spread out and migrated away from each other (Figure 2.3B). 
Protein levels of OCT4 and NANOG were also downregulated after 6 days of 5 M 
Displg treatment, yet SOX2 expression stayed roughly unchanged during this period 
(Figure 2.3C). FACS analysis under the same treatment condition also showed that, 
although the majority of cells lost OCT4 and NANOG expression on day 6, 
approximately 25% of the cells remained OCT4+NANOG+ (Figure 2.3D), indicating that 
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roughly 1/4 of the population remained pluripotent even after 6 days of Displg treatment 
at 5 M. 
 
To achieve a more robust differentiation, I tested Displg at higher concentrations. 
I found that a 10 M concentration was sufficient for Displg to nearly completely 
annihilate the OCT4+NANOG+ population (from 88.29% to 0.67%; Figure 2.4A) after 
only 4 days of treatment. Western blotting showed similar results at the protein level 
(Figure 2.4B).  
 
Both FACS analysis and Western blotting results showed that protein levels of the 
pluripotency markers OCT4, NANOG, and SOX2 remained largely unchanged after 24 
hours of 10 M Displg treatment (Figures 2.4A and 2.4B). In contrast, quantitative PCR 
(qPCR) results indicated that the mRNA levels of OCT4 and NANOG decreased within 
24 hours of 10 M Displg treatment, and continued to decrease during the remaining 
course of differentiation (Figure 2.4C). These results showed that, upon Displg treatment, 
the changes of pluripotency marker expressions at the mRNA level preceded that at the 
protein level, indicating that the primary regulatory pathway affected by Displg may be 
related to the regulation of mRNA. 
 
I then examined whether Displg induced lineage-specific differentiation of hESCs. 
qPCR results failed to show consistent elevation of any lineage-specific markers (Figure 
2.5), indicating that Displg, although potently disrupts hESC pluripotency, is unable to 
induce lineage-specific differentiation. This result suggested that the biological target of 
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Displg most likely maintained pluripotency through direct-support of the core regulatory 
network rather than by blocking differentiation toward a specific lineage. 
 
Displg disrupts hESC pluripotency by targeting HSPA8  
To identify the biological target of Displg, I synthesized a biotinylated version of 
the compound by linking a linker and a biotin molecule at the -OH site of Displg (Figure 
2.6A); this molecule is hereafter referred to as Displg-biotin. Displg-biotin disrupted 
hESC pluripotency, as shown by loss of colony integrity (Figure 2.6B) and 
downregulation of OCT4 (Figure 2.6C), although at a higher dosage (50 M) compared 
to unmodified Displg. This result indicates that Displg-biotin reserves the bioactivity of 
its parent-compound Displg, although with a weaker potency. The decrease in potency of 
Displg-biotin may be due to the larger size of the molecule preventing its cellular uptake.  
 
Using Displg-biotin as a probe, I performed an affinity-based pull-down 
experiment (Materials and Methods). Briefly, hESCs treated with Displg-biotin or DMSO 
control were lysed and then incubated with Streptavidin beads. Proteins bound to Displg-
biotin were eluted and analyzed using SDS-PAGE followed by silver staining. Four 
distinct bands were consistently detected in the Displg-biotin pull-down samples but not 
in the control samples (Figure 2.7). Using mass spectrometry analysis, I identified the 
proteins contained in those bands as heat shock 70kDa protein 8 (HSPA8, also known as 
HSC70) isoform 1, telomere maintenance 2 (TELO2), SERPINE1 mRNA binding protein 
1 (SERBP1), and nucleophosmin (NPM1), respectively (Figure 2.7).  
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One of the target proteins, HSPA8, caught my attention. HSPA8 is the 
constitutively expressed member of the 70 kd heat-shock protein family, as opposed to 
the stress-induced HSP70.  Two previous publications (Fathi et al., 2009; Son et al., 2005) 
and my data (Figure 2.8) showed that HSPA8 is expressed in undifferentiated hESCs but 
downregulated upon differentiation, revealing a link between HSPA8 expression and 
hESC pluripotency. I thus hypothesized that HSPA8 may be the biological target of 
Displg.  
 
Before testing this hypothesis, I confirmed the interaction between Displg and 
HSPA8 by applying the pull-down samples to Western blotting which showed that Displg 
indeed bound to and pulled down HSPA8 (Figure 2.9A). I also performed an in vitro 
ATPase assay using recombinant HSP70 which is structurally highly similar to HSPA8 
(Stricher et al., 2013), and showed that Displg inhibited the ATPase activity of HSP70 
with an IC50 of 225 M (Figure 2.9B). These results confirmed HSPA8 as a target of 
Displg.  
 
I then conducted loss-of-function experiments to examine whether HSPA8, and 
not the other proteins bound by Displg, was the true biological target of Displg in regard 
to its activity in disrupting pluripotency. Knock-down of HSPA8 in hESCs using 
shRNAs disrupted pluripotency, as shown by loss of colony integrity (Figure 2.10A) and 
downregulation of pluripotency markers OCT4, NANOG, and SOX2 (Figure 2.10B). 
Other commercially available HSP70/HSPA8 inhibitors including Apoptozole (Cho et al., 
2011) (20 M) and VER155008 (Massey et al., 2010) (20 M) also disrupted hESC 
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pluripotency, although less potently compared to Displg (Figure 2.10C). On the other 
hand, knock-down of the other protein targets pulled down by Displg, including NPM1, 
SERBP1, and TELO2, failed to disrupt hESC pluripotency (Figures 2.11). These results 
demonstrated that HSPA8 is most likely to be the biological target of Displg which is 
responsible for maintaining hESC pluripotency.  
 
To further verify HSPA8 as the primary target of Displg in pluripotency 
maintenance, I attempted to rescue the pluripotency-disruption effect of Displg by 
overexpressing HSPA8 in hESCs. I first overexpressed wild-type HSPA8 protein, which 
rescued the effect of Displg, as shown by the elevated OCT4 expression (Figure 2.12A). 
The efficiency of this rescue was modest, which may be attributed to the fact that 
overexpression of wild-type chaperone proteins has been known to be harmful to cells 
(Freeman et al., 1995). To achieve a more robust rescue, I overexpressed a chaperone-
dead mutant form of HSP70 protein named HSP70-AAAA (Freeman et al., 1995), in 
which the last 4 amino acids were mutated from EEVD to AAAA. Indeed, 
overexpression of HSP70-AAAA gave rise to a more robust rescue of Displg as 
demonstrated by the pluripotency marker expressions (Figure 2.12B). These results 
confirmed HSPA8 as the biological target of Displg, and further verified the function of 
HSPA8 in pluripotency maintenance. 
 
HSPA8 maintains pluripotency by facilitating the DNA-binding activity of OCT4 
Heat shock proteins, as molecular chaperones, are involved in a variety of cellular 
processes such as maintenance of protein stability (Wegele et al., 2004) and mediating 
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the assembly and disassembly of protein complexes (Ellis, 2007). More recently 
researchers discovered that heat shock proteins also play an important role in regulating 
the dynamics of protein-DNA association events such as transcription (Freeman and 
Yamamoto, 2002; Muller et al., 2004; Shaknovich et al., 1992; Stavreva et al., 2004; 
Walerych et al., 2004). I thus attempted to examine the effect of HSPA8 on the activity of 
the core transcription factor network of pluripotency. For simplicity, I focused my study 
on the interaction between HSPA8 and OCT4 which is the master regulator of 
pluripotency. Indeed, co-IP experiments showed that HSPA8 bound to OCT4, and that 
this interaction was disrupted by Displg (Figure 2.13). 
 
My data showed that the downregulation of core pluripotency factors at the 
mRNA level preceded the downregulation of those factors at the protein level (Figure 
2.4); specifically, mRNA levels of the pluripotency factors were downregulated within 
the first 24 hours of Displg treatment (Figure 2.4C), whereas their protein levels 
remained largely unchanged after 24 hours of treatment (Figures 2.4A and 2.4B). This 
distinct dynamic indicated that HSPA8 most likely regulates the core pluripotency 
network at the mRNA level.  
 
I thus hypothesized that HSPA8 maintains pluripotency through facilitating the 
transcription-activation activity of OCT4. To test this hypothesis, I examined whether 
HSPA8 was required for OCT4 protein to efficiently bind to DNA. I first tested this 
potential regulatory mechanism using electrophoretic mobility shift assay (EMSA), and 
discovered that Displg decreased the binding affinity of OCT4 to its DNA-binding motifs 
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found in the OCT4, NANOG, and SOX2 promoters (Catena et al., 2004; Chew et al., 2005; 
Rodda et al., 2005). Two distinct bands (A & B; Figure 2.14A) were detected in EMSA; a 
supershift assay using anti-OCT4 antibody was conducted which showed band-A as the 
band representing OCT4-binding to the DNA probes (Figure 2.14B). This data indicate 
that the activity of HSPA8 was necessary for OCT4 protein to efficiently bind to DNA. I 
then examined whether this regulatory effect depends on the presence of other protein 
factors by conducting an in vitro binding assay using recombinant OCT4 and HSP70 
proteins. OCT4 alone only exhibited a weak binding affinity to DNA, whereas the 
addition of 1 - 10 M recombinant HSP70 dramatically enhanced the OCT4-DNA 
interaction (Figure 2.15). This result suggests that HSPA8 facilitates the association of 
OCT4-DNA complexes in a direct fashion independent of other protein factors. 
 
Discussion 
In this study, I established a NTERA-2 hECC-based pluripotency reporter system 
and screened 171,077 compounds. I identified 29 bioactive small molecules that potently 
disrupted hESC pluripotency as evidence by changes in pluripotency marker expressions, 
and studied one particular molecule, Displurigen, in detail. Using target identification 
techniques and functional verifications I discovered HSPA8 as the biological target of 
Displurigen. 
 
HTS has been used for the discovery of novel small molecule compounds that 
regulate pluripotent stem cell (PSC) fate; such studies require the use of pluripotent cell 
lines as screening platforms. Commonly available pluripotent platforms include mouse 
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and human embryonic stem cells (ESCs), mouse and human embryonal carcinoma cells 
(ECCs), and the more recently established mouse and human induced-pluripotent stem 
cells (iPSCs). The earliest attempts of pluripotency-regulator screenings adopted mouse 
embryonic stem cells (mESCs) and mouse embryonal carcinoma cells (mECCs) as their 
screening platforms (Chen et al., 2006a; Ding et al., 2003). More recently, several hESC-
based HTSs have been reported (Barbaric et al., 2010; Desbordes et al., 2008; Xu et al., 
2010a). Compared to hESCs, mESCs and mECCs are better platforms for HTS: they are 
easier to passage and maintain, and are less prone to spontaneous differentiation. 
However, to achieve deeper understandings to human stem cell pluripotency and 
differentiation as demanded by practical applications such as regenerative medicine 
requires more robust platforms for pluripotency-related HTSs. A recent study by Caron et 
al. attempted to solve this problem by adopting a genetically abnormal hESC line with 
characteristics that make it favorable to HTS; they have yet to perform an actual HTS 
using this model (Caron et al., 2013). Barbarics et al. chose to use unmodified NTERA-2 
cells as their screening platform and conducted a morphology based screen to search for 
pluripotency regulators, but were only able to screen 80 compounds using their method. 
To date, there have been no reports of truly “high-throughput” screenings conducted 
using hECC-based platforms. Therefore my system represents the first hECC-based HTS 
platform which has been proven effective through an actual screen. 
 
Heat-shock proteins, as molecular chaperones, are involved in a variety of cellular 
functions. Apart from their commonly known roles in maintaining protein stability and 
mediating the assembly and disassembly of protein complexes, recent studies showed that 
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certain chaperones, including HSPA8, also regulate the dynamic formation of protein-
DNA complexes involved in biological processes such as transcription, telomere 
maintenance, DNA repair and DNA replication (Ahn et al., 2005; DeZwaan and Freeman, 
2010). My study unveiled a novel function of HSPA8 in maintaining hESC pluripotency 
by facilitating the DNA-binding, and subsequently, transcription-activation activities of 
the master pluripotency factor OCT4. This is the first report demonstrating a direct 
involvement of a chaperone protein in the regulation of pluripotency.  
 
My study also adds to the current reservoir of bioactive small molecules a novel 
HSPA8/HSP70 inhibitor, Displurigen. Modulation of heat-shock protein activities has 
been extensively studied for potential clinical applications such as cancer therapy. In 
contrast to normal cells, cancer cells strongly overexpress HSP70 in order to provide 
resistance to stresses generated by the environment, from tumorigenesis events, and 
during cancer therapy. This addiction to HSP70 provides the theoretical basis for its 
targeting in anti-cancer treatment (Goloudina et al., 2012; Jego et al., 2013). In the recent 
years, several novel HSPA8/HSP70 inhibitors have been discovered and studied for anti-
cancer therapies (Goloudina et al., 2012). The discovery of Displurigen expands this 
growing list of HSPA8/HSP70 inhibitors and provides a novel drug candidate for cancer 
therapy.  
 
In summary, by establishing and applying a hECC-based HTS system, my study 
identified a novel chemical inhibitor of HSPA8/HSP70, and unveiled a previously 
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uncharacterized, chaperone-related molecular mechanism for the maintenance of hESC 
pluripotency.   
 
Materials and Methods 
Cell culture 
H9 and H1 hESC lines (WiCell Research Institute, Madison, WI) were 
maintained under a feeder condition or a feeder-independent condition. For the feeder 
condition (Thomson et al., 1998), primary mouse embryonic fibroblasts (MEFs) prepared 
from embryos of pregnant CF-1 mice (day 13.5 of gestation; Charles River) were 
cultured in Dulbecco’s Modified Eagle Medium (DMEM) containing 10% FBS 
(Hyclone), 1% non-essential amino acids (NEAA; Invitrogen), and 
penicillin/streptomycin, and mitotically inactivated by gamma irradiation. H9 and H1 
hESCs were cultured on irradiated MEFs in media containing DMEM/F12, 20% 
knockout serum replacement (KSR; Invitrogen), 4 ng/ml basic fibroblast growth factor 
(bFGF) (Invitrogen), 1% NEAA, 1 mM glutamine, and 0.1 mM β-mercaptoethanol. For 
the feeder-independent condition, hESCs were cultured on Matrigel (BD Biosciences)-
coated plates in mTeSR1 medium (StemCell Technologies) as described (Ludwig et al., 
2006). The experiments described in this study were conducted with H9 and H1 hESCs 
between passages 30 and 60. NTERA-2 cells (NTERA-2 cl.D1) were purchased from 
American Type Culture Collection (ATCC) and were cultured in Dulbecco's Modified 
Eagle's Medium (DMEM) containing 10% fetal bovine serum. 
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Generation and validation of NTera-2-OP4k reporter cells  
The plasmid containing EGFP driven by a fragment of OCT4 promoter (~4 kb) 
was kindly provided by Dr. Wei Cui (Imperial College London) and was as described 
(Gerrard et al., 2005). We established NTERA-2-OP4k cells containing the OCT4-EGFP 
construct by transfecting cells using Amaxa Nucleofection System (Nucleofector Kit L; 
Program X-001), selecting transfected cells with G418 (500 μg/ml, 2 weeks), and 
enriching EGFP-positive cells using fluorescence-activated cell sorting (FACS) 
(Cytomation Plus, Dako).  
 
For validation of reporter activity, NTERA-2-OP4k cells were plated at a density 
of 0.1 – 0.25 × 105 cells/cm2 and incubated with RA (Sigma; 10 μM), HMBA (Sigma; 3 
mM), bFGF (Invitrogen; 4 ng/ml), and Y-27632 (Calbiochem; 10 μM). After 6 - 7 days 
of incubation, changes in the level of EGFP signals were examined using fluorescent 
microscopy (Zeiss), flow cytometry (BD Biosciences LSR II), and fluorescent plate 
reader (Analyst HT, Molecular Devices).   
 
Large-scale chemical screening 
Large-scale chemical screening was conducted at the High-Throughput Screening 
Facility (HTSF) at the University of Illinois at Urbana−Champaign 
(http://www.scs.illinois.edu/htsf/index.html). The HTSF hosts 171,077 compounds from 
several compound libraries, which include the Marvel Library, the HTSF House Library, 
the ChemBridge MicroFormat Library, and the National Cancer Institute (NCI) library.  
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For large-scale chemical screening, NTERA-2-OP4k cells were trypsinized and 
seeded onto 96/384-well plates (at 0.1 – 0.25 × 105 cells/cm2) using a WellMate 
Microplate Dispenser (Matrix). Compounds were added immediately after plating using a 
96-well or a 384-well pin-tool. The first two and last two columns of 384-well plates and 
the first and last column of 96-well plates were used for DMSO treatment as negative 
controls. Cells were incubated for 6 - 7 days without medium change. EGFP expressions 
of individual wells were recorded by the fluorescence plate reader (Analyst HT, 
Molecular Devices). EGFP signal detected with compound treatments were compared to 
the DMSO control, and those with significant reduction (>30%; average level of 
background signals subtracted before comparison) were marked as potential hits and 
were subsequently inspected visually using a fluorescence microscope (Zeiss). The final 
compound concentrations applied to the screening plates were 5 - 10 μM (Marvel library), 
500 nM - 1 μM (NCI library), 5 - 10 μM (House library), and 10 - 20 μg/ml (ChemBridge 
MicroFormat library).   
 
Western blotting 
Cultured cells were lysed directly by 2× Laemmli buffer (Bio-Rad), boiled for 5 
min, and analyzed using SDS-PAGE electrophoresis followed by wet-transfer onto 
nitrocellulose membranes using a system manufactured by Bio-Rad. The membranes 
were blocked using blocking solution (5% BSA in Tris-buffered saline containing 0.1% 
Tween-20 [TBST]), and then incubated with primary antibodies, diluted in TBST, at 4°C 
overnight. The membranes were then washed by TBST for 3 × 5 min, and incubated with 
horseradish peroxidase (HRP) conjugated secondary antibodies at room temperature for 
37 
 
1 hr. Finally, the membranes were washed 5 min each time for 3 – 5 times by TBST and 
developed using Super-Signal West Pico Chemiluminescent Substrate (Pierce).  
 
RNA extraction, reverse transcription, and quantitative-PCR 
Total RNA were isolated using RNeasy mini kit (QIAGEN). cDNAs were 
synthesized from the purified RNAs using Reverse Transcription System (Promega). 
Quantitative-PCR was performed using QuantiTech SYBR Green PCR kit (QIAGEN). 
Signals were analyzed using the comparative CT method, and ACTB gene was used as an 
internal control.   
 
Flow cytometry  
Single cell suspensions were acquired through Accutase (Invitrogen) treatment. 
Cells were fixed and stained using the Transcription Factor Buffer Set (BD Biosciences) 
following the manufacturer’s instructions. Conjugated antibodies including OCT4A-
Alexa647 and NANOG-PE were used. Cells were resuspended in PBS supplemented 
with 1% BSA and analyzed using a BD Biosciences LSR II flow cytometry analyzer and 
BD FACSDiva software.  
 
Affinity chromatography, electrophoresis, and silver staining  
hESCs were cultured under the feeder-independent condition with or without the 
presence of displurigen-biotin (10 µM) overnight, washed in PBS three times and lysed 
in Ice-cold RIPA buffer supplemented with protease and phosphatase inhibitors cocktail 
(Sigma). The lysates were then diluted two-fold by Tris buffer (50 mM Tris-HCl, pH 7.5). 
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For affinity chromatography (“pull-down”), diluted lysates were incubated with 
streptavidin−agarose beads (Sigma) for 5 hr at 4°C. The beads were collected using 
centrifugation and washed with wash buffer (75 mM NaCl, 0.5 mM EDTA, 0.5% Triton 
X-100, 0.5% sodium deoxycholate, 0.05% SDS, 50 mM Tris-HCl, pH 7.6). The washed 
beads were suspended in 2× Laemmli buffer (Bio-Rad) and heated at 100°C for 5 min. 
 
For electrophoresis and silver staining, 10 μl samples were loaded on 
polyacrylamide gel. Silver staining was performed using ProteoSilver Plus Silver Stain 
Kit (Sigma). Protein bands detected by silver staining were selectively excised for mass 
spectrometry analysis. 
 
Lentivirus production and infection 
For viral packaging, expression vectors were co-transfected with pCMV-dR8.91 
and pCMV-VSV-G into 293T cells by CaPO4 precipitation. After overnight incubation, 
culture medium was replaced by virus-packaging medium containing DMEM, 30% FBS, 
and 1 mM sodium pyruvate. Supernatants were collected 48 hr later and concentrated 
approximately 100× by ultracentrifuge (20,000 rpm, 1 hr). H1 and H9 hESCs were 
infected by virus concentrates in the presence of Polybrene (6 μg/ml), and then subjected 
to puromycin (0.5 μg/ml) selection for 3-5 days prior to analysis. 
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Synthesis of Displurigen-biotin 
S
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K2CO3, n-Bu4NI,
TFA
CH2Cl2 HATU, TEA, DMF
DMF
 
Synthesis of Compound 2: Compound 1 (0.0055 g, 0.019 mmol), 2-[2-(2-
tertbutoxycalbonyl aminoethoxy) ethoxy]ethyl bromide (0.0071 g, 0.023 mmol), K2CO3 
(0.0030 g, 0.022 mmol) and n-Bu4NI (0.0014 g, 0.0038 mmol) were suspended in DMF 
(1 mL). The suspension was heated at 60 °C for 12 h. After evaporation of the solvent, 
crude product was purified by flash chromatography on silica gel (EtOAc : Hexanes = 1 : 
1) and then EtoAc to give 2 as solid (0.0086 g, 0.0166 mmol, 86.5 %). 1H NMR 
(300MHz, CDCl3, 25 oC) δ 1.43 (s, 9H), 3.29 (m, 2H), 3.53 (t, J = 5.1 Hz, 2H), 3.58 (m, 
2H), 3.76 (m, 2H), 3.99 (t, J = 4.5 Hz, 2H), 4.40 (t, J = 4.8 Hz, 2H), 4.98 (bs, 1H), 6.73 (s, 
1H), 7.42-7.62 (m, 4H), 7.68 (t, J = 6.9 Hz, 1H), 7.83-7.90 (m, 3H); 13C NMR (75 MHz, 
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CDCl3, 25 oC) 28.4, 40.4, 69.3, 70.2, 70.4, 70.5, 71.4, 119.9, 120.4, 127.8, 129.1, 130.0, 
131.6, 133.8, 154.5, 155.9, 156.6, 178.4 
 
Synthesis of Compound 3: Deprotection of 2 (0.0086 g, 0.0166 mmol) was 
performed with 0.5 mL of CH2Cl2 and 0.2 mL TFA at 0 °C. After stirring at 0 °C for 3 h, 
the reaction mixture was concentrated. Toluene (0.5 mL) was added to the residue and 
then evaporated to remove TFA. The procedure was repeated three times. The resulting 
TFA salt of the deprotected amine was dissolved in DMF (1 mL) and D-biotin (0.0071 g, 
0.029 mmol). HATU (0.012 g, 0.0316 mmol) was added followed by a triethylamine (25 
μL, 0.18 mmol). After stirring at rt overnight, the mixture was concentrated under 
reduced pressure and the residue was purified by flash chromatography on silica gel 
(CHCl3 : EtOH = 10 : 1), which gave 3 (0.0077 g, 0.012 mmol, 72.1 %) as solid. 1H NMR 
(300 MHz, CDCl3, 25 °C) δ 1.37 (m, 2H), 1.68 (m, 4H), 2.15 (t, J = 7.5 Hz, 2H), 2.70 (d, 
J = 12.9 Hz, 1H), 2.88 (dd, J = 5.4 Hz, J = 12.9 Hz, 1H), 3.09 (m, 1H), 3.40 (m, 2H), 
3.56 (t, J = 5.1 Hz, 2H), 3.67 (m, 2H), 3.78 (m, 2H), 3.98 (t, J = 4.8 Hz, 2H), 4.23 (m, 
1H), 4.40 (m, 2H), 4.47 (m, 1H), 4.93 (s, 1H), 5.77 (s, 1H), 6.50 (t, 1H), 6.75 (s, 1H), 
7.42-7.60 (m, 4H), 7.66 (t, J = 7.5 Hz, 1H), 7.84 (m, 3H); 13C NMR (75 MHz, CDCl3, 25 
oC) 25.8, 28.3, 36.1, 39.4, 40.8, 55.7, 60.4, 62.0, 69.4, 70.2, 70.6, 70.7, 71.2, 120.0, 120.7, 
128.2, 129.4, 130.3, 131.9, 134.2, 154.6, 156.7, 164.0, 173.5, 178.6; MS (ESI+) (m/z): [M 
+ H]+ Calcd. For C31H38N3O8S2: 644.2095; Found: 644.2104.  
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Mass spectrometry analysis 
In UIUC MS facility: Gel slices were dehydrated and destained in 50% 
Acetonitrile + 25 mM NH4HCO3 and gently crushed using a plastic pestle inside a 1.5 
ml eppendorf tube. The crushed gel was dried briefly using Speedvac (Thermo) before 
digestion with Trypsin (mass spectrometry grade, G-Biosciences at 1:50 w/w) in 25 mM 
ammonium bicarbonate. Digestion was performed using a CEM Discover Microwave 
Digestor (Mathews, NC) for 15 min at 75 watts, 55°C. The digested peptides were 
extracted using 50% acetonitrile and 5% formic acid, lyophilized and reconstituted in 5% 
acetonitrile and 0.1% formic, 10 µl of which was used for LC/MS analysis. 
 
Mass spectrometry was performed using a Waters Q-ToF connected to a Waters 
nanoAcquity UPLC (Milford, MA). Column was a Waters Atlantis dC18 nanoAcquity 
UPLC column 75 µm x 150 mm (3 µm particle size) running at 250 nl/min. Gradient was 
from 100% A to 60% B (A: water and 0.1% formic acid; B: acetonitrile and 0.1% formic 
acid).  Data collection was performed using MassLynx 4.1 (Waters). The top 4 intensive 
precursor ions from each survey scan were subjected to MS/MS by Collision Induced 
Dissociation (CID). The raw mass spectrometric data were processed using ProteinLynx 
Global Server 2.2.5 (Waters). The refined peaklists were analyzed using Mascot 2.2 
(Matrix Science, London, UK) with a tolerance of ± 0.4 Da for both the precursor ions 
and fragment ions. Searches were carried out using the NCBI non-redundant protein 
database. 
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In UC-Riverside MS facility: Each gel band was destained (1:1 mixure of 30 mM 
K3Fe (CN)6 and 100 mM Na2S2O3), then dehydrated with acetonitrile, and digested 
with sequencing grade trypsin (10µg/mL) overnight at 37 oC. The resulting peptides were 
extracted and prepared as previously described (Carter et al., 2004). A nano-
UPLC/MS/MS analysis was performed using combination of the nano-Acquity UPLC 
and Q-TOF Premier (Waters) following the method in a previous study (Rosado et al., 
2010). 
 
Embryoid body (EB) formation 
H9 and H1 hESC colonies were dissociated from the culture surface by 20 min 
treatment of Dispase (Invitrogen). Suspended colonies were pooled by brief 
centrifugation (1000 rpm, 1 min), resuspended in medium containing Advanced RPMI 
1640 (Invitrogen), 2% B-27 supplement (Invitrogen), and 1% Glutamax (Invitrogen), and 
then plated into ultra-low attachment plates (Corning). Medium was changed every other 
day. 
 
In vitro ATPase assay  
The HSP70 ATPase rates were determined as described (Freeman et al., 1995). In 
brief, ATP hydrolysis was determined by measuring the release of [32P]Pi from [-
32P]ATP. The ATPase rates were calculated utilizing an average [-32P]ATP hydrolysis 
rate at each time point (5, 10, 15 and 20 min) from three separate experiments after the 
background hydrolysis was subtracted.  The data were visualized and quantified by 
PhosphorImager analysis (Molecular Dynamics). The effect of displurigen on the ATPase 
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rate of HSP70 was measured by incubating HSP70 (5 min) with varying levels of 
displurigen prior to the introduction of ATP.   
 
HSPA8 overexpression plasmid construction 
HSPA8-isoform-1 cDNA clone was purchased from OriGene (SC322471), and 
subcloned into a pSin-EF2 plasmid (Addgene; modified with a short adaptor sequence) at 
the MluI/NdeI site. 
 
Immunoprecipitation 
Cells treated with DMSO or Displg (100 μM, 2 hours) were lysed in ice-cold 
RIPA buffer (Pierce) supplemented with a protease inhibitor cocktail (Sigma). After 
clarification, cell lysates were pre-cleared with Protein A/G magnetic beads (Pierce) and 
thereafter incubated with 2 μg of anti-OCT4 antibody (Santa Cruz) and with DMSO or 1 
mM Displg, respectively. After 2 hours of incubation at 4°C, Protein A/G magnetic beads 
were added to the cell lysates. The resulting immunoprecipitates were washed with ice-
cold PBS and analyzed by Western blotting. 
 
Electrophoretic mobility shift assay (EMSA) 
EMSA analysis was performed using Buffer C nuclear extracts (10 g) from 
hESCs. The extracts were incubated with poly dI-dC (Sigma) and 32P-end labeled 
oligonucleotides: OCT4, NANOG and SOX2 binding sequence probes along with the 
complimentary primers. The protein-DNA complexes were resolved by native 
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polyacrylamide gel (4%) electrophoresis and the dried gels were visualized using a 
PhosphorImager (Molecular Dynamics). 
 
In vitro OCT4-DNA binding assay 
OCT4 cDNA was cloned from the pSin-EF2-OCT4-Pur vector (Addgene) and 
inserted into the PET-24a protein expression vector, which contains a C-terminal His Tag. 
OCT4 and HSP70 proteins were expressed in Rosetta cells and captured with the Talon 
metal affinity resin (Clontech). The proteins were further purified using Resource Q and 
Superdex 200 columns (GE Healthcare). OCT4 protein binding to the OCT4 response 
element was assessed by the use of EMSA analysis in the presence or absence of purified 
HSP70 protein.  
 
Statistical analysis 
Statistical analyses were performed using Microsoft Excel. Student’s t-test was 
used to compare two experimental groups, assuming unequal variances.  Differences are 
considered significant when p < 0.05. 
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Figure 2.2. (Cont.) 
(B) Schematic representation (top panel) of several cellular outcomes of NTERA-2-OP4k 
cells after the chemical screening. Representative fluorescent (middle panel) and phase-
contrast (bottom panel) images were taken from the actual screening and are shown for 
each outcome. Scale bar: 100 μm. (C) Number of total compounds screened and hit 
compounds identified after each step of screening. The hit rates (in parenthesis) were 
calculated based on the ratio of hit compounds and total compounds. Compounds from 4 
different libraries (Marvel, NCI, House, and ChemBridge library) were screened. Due to 
the large number of compounds hosted by the libraries (171,077 compounds total), only 
one round of screening (n = 1) was performed for the entire compound collection.  
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Tables 
Antibody Source Catalog Number Dilution 
OCT4 Santa Cruz sc-9081 1:1,000 (WB) / 1:100 (IF) 
SOX2 Millipore AB5603 1:500 (WB) 
NANOG Cell Signaling 4903P 1:500 (WB) 
α-TUBULIN Abcam ab11304 1:10,000 (WB) 
HSPA8-Isoform-I R&D systems MAB4148 1:100 (WB) 
HSP70 Abcam ab5439 1:1000 (WB) 
TELO2 Santa Cruz sc-138069 1:200 (WB) 
SERBP1 Santa Cruz sc-131741 1:200 (WB) 
NPM1 Santa Cruz sc-6013-R 1:200 (WB) 
OCT4A-Alexa647 BD Biosciences 562252 1:20 (FACS) 
NANOG-PE BD Biosciences 560483 1:5 (FACS) 
(WB: Western blotting; IF: immunofluorescence) 
 
Table 2.1. Antibody sources and dilutions 
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Primer Name Forward Primer (5'-3') Reverse Primer (5'-3') 
ACTB agagctacgagctgcctgac cgtggatgccacaggact 
OCT4 (isoform A) cttctcgccccctccaggt aaatagaacccccagggtgagc 
NANOG tttggaagctgctggggaag gatgggaggaggggagagga 
SOX2 ggcagctacagcatgatgcaggagc ctggtcatggagttgtactgcagg 
T (Brachyury) gctgtgacaggtacccaacc catgcaggtgagttgtcagaa 
MIXL1 ggcgtcagagtgggaaatcc gcagttcacatctacctcaagag 
CER1 acagtgcccttcagccagact acaactactttttcacagccttcgt 
AFP agcttggtggtggatgaaac ccctcttcagcaaagcagac 
CGB7 tccttggcgctagaccac cagggaggcacaggagtg 
SOX1 tacagccccatctccaactc gctccgacttcaccagagag 
PAX6 atttcccgctctggttcag tagcgaagcctgacctctgt 
 
Table 2.2. Names and sequences of qPCR primers 
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Target shRNA Sequence (5’ – 3’) 
HSPA8-1 
HSPA8-1-1 ccgggcaactgttgaagatgagaaactcgagtttctcatcttcaacagttgctttttg 
HSPA8-1-2 ccggccaagacttcttcaatggaaactcgagtttccattgaagaagtcttggtttttg 
HSPA8-1-3 ccgggcccgatttgaagaactgaatctcgagattcagttcttcaaatcgggctttttg 
TELO2 
TELO2-1 ccggatctgacctcacagttctatgctcgagcatagaactgtgaggtcagattttttg 
TELO2-2 ccggagaacaagaaggcccagtttgctcgagcaaactgggccttcttgttcttttttg 
TELO2-3 ccggcctgatgtgcctggctgttaactcgagttaacagccaggcacatcaggtttttg
TELO2-4 ccggtgaccacgtctgaggacatagctcgagctatgtcctcagacgtggtcatttttg
TELO2-5 ccggtagtgcagccagtccgctaaactcgagtttagcggactggctgcactatttttg
SERBP1 
SERBP1-1 ccgggcgcttaagaaagaaggaatactcgagtattccttctttcttaagcgcttttttg 
SERBP1-2 ccgggattcggttatggaccatcatctcgagatgatggtccataaccgaatcttttttg 
SERBP1-3 ccggcctgaaggtgaagaacatcatctcgagatgatgttcttcaccttcaggttttttg 
SERBP1-4 ccgggccgaggagatggatttgattctcgagaatcaaatccatctcctcggcttttttg
SERBP1-5 ccggcctgaaggtgaagaacatcatctcgagatgatgttcttcaccttcaggtttttg 
NPM1 
NPM1-1 ccgggccaagaatgtgttgtccaaactcgagtttggacaacacattcttggctttttg 
NPM1-2 ccgggccgacaaagattatcactttctcgagaaagtgataatctttgtcggctttttg 
NPM1-3 ccgggcgccagtgaagaaatctatactcgagtatagatttcttcactggcgctttttg 
NPM1-4 ccgggcaaaggatgagttgcacattctcgagaatgtgcaactcatcctttgctttttg 
NPM1-5 ccggcctagttctgtagaagacattctcgagaatgtcttctacagaactaggtttttg 
 
Table 2.3. Names and sequences of shRNAs  
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Probe Name Forward Sequence (5'-3') Reverse Sequence (5'-3') 
NANOG tctgcagctacttttgcattacaatggccttggtgag ctcaccaaggccattgtaatgcaaaagtagctgcaga 
OCT4 cagacagcagagagatgcatgacaaaggtgccgtgatggttc 
gaaccatcacggcacctttgtcatgcatctctctgctgtc
tg 
SOX2 gccgtttgccttcatttccataagaagattaaga tcttaatcttcttatggaaatgaaggcaaacggc 
 
Table 2.4. EMSA probes 
65 
 
CHAPTER 3: A NOVEL SMALL MOLECULE INHIBITOR OF TRPM6 
PROMOTES NEARLY HOMOGENEOUS MESODERM AND DEFINITIVE 
ENDODERM DIFFERENTIATIONS OF HUMAN PLURIPOTENT STEM 
CELLS AND REVEALS A ROLE OF MAGNESIUM HOMEOSTASIS DURING 
GERM LAYER SPECIFICATION 
 
Abstract 
Cell-replacement therapies require differentiated cells of high purity, yet current 
human pluripotent stem cell-based differentiation protocols perform poorly in meeting 
this requirement. In this study, I optimized growth factor-directed mesoderm and 
definitive endoderm (DE) differentiation protocols to maximize their efficiencies. 
Moreover, through a chemical screen, I discovered a novel small molecule Mesendogen 
(MEG) which robustly induces nearly homogeneous (≥85%) mesoderm and DE 
differentiations of human pluripotent stem cells when combined with the optimized 
protocols. Intracellular FACS analyses with stringent gate settings for multiple lineage-
specific markers were used to rigorously discriminate and precisely quantify the 
mesoderm and DE progenitor populations generated in this study. Using a kinome screen 
I identified transient receptor potential cation channel, subfamily M, member 6 (TRPM6) 
as a potential target of MEG. The expression of TRPM6 is tightly controlled during 
animal development, and loss-of-function mutation of TRPM6 has been reported to cause 
developmental defects. The hetero-tetrameric channel complex formed by TRPM6 and 
TRPM7 is the major regulator of cellular and whole body magnesium homeostasis, yet 
the exact roles of TRPM6/TRPM7 channel and magnesium homeostasis during 
development are poorly understood. Loss-of-function experiments confirmed TRPM6 as 
the biological target of MEG. I further demonstrated that MEG reduces cellular 
magnesium level, and magnesium-withdrawal phenocopies MEG, indicating that MEG 
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may exert its biological function by inhibiting TRPM6/TRPM7 magnesium channel 
activity and thus modulating cellular magnesium uptake. This study describes a robust 
method for the highly dependable productions of nearly homogeneous mesoderm and DE 
progenitors, and reveals for the first time that TRPM6 and magnesium homeostasis are 
involved in the regulation of early germ layer specification. 
  
Introduction 
Fulfilling the promises of hPSC-based cell-replacement therapy requires the 
development of robust differentiation protocols that can produce terminally differentiated 
cellular progenies possessing relevant biological functions, in large quantities, and with 
high purities (Lee et al., 2009; Passier, 2003; Yabut and Bernstein, 2011). Because the 
majority of current differentiation protocols are built on a step-wise design (Cai et al., 
2007; Chambers et al., 2009; Chen et al., 2009; D'Amour et al., 2006), each step of 
differentiation must be optimized in these protocols in order to achieve maximum 
efficiencies for the productions of the end products. For this purpose, bioactive small 
molecules have been widely applied to increase differentiation efficiencies toward 
multiple lineages with success (Borowiak et al., 2009b; Chen et al., 2009; Chen et al., 
2012; Chetty et al., 2013; Gonzalez et al., 2011a; Lian et al., 2012; Mahmood et al., 2010; 
McLean et al., 2007; Zhu et al., 2009). 
 
In the first part of this study, through a small scale chemical screen, I discovered a 
small molecule which I named Mesendogen (MEG for short) that robustly enhances the 
growth factor-induced mesoderm and DE differentiations of human embryonic stem cells 
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(hESCs) and human induced pluripotent stem cells (hiPSCs) to near-homogeneity (≥
85%). Both pre-treatment and combined treatment of MEG dramatically and consistently 
boosted the effects of mesoderm- and DE-inducing growth factors. The time window for 
this enhancement effect of MEG seems to be restricted to the very early stage of 
differentiation (within the first 24 hours), as delayed treatments of MEG failed to enhance 
differentiation. 
 
Transient receptor potential cation channel, subfamily M, member 6 (TRPM6), 
together with another member of the TRPM protein family, transient receptor potential 
cation channel, subfamily M, member 7 (TRPM7), are a special type of kinase commonly 
referred to as the "channel kinases", in that they contain both a intracellular kinase 
domain and a transmembrane channel domain (Chubanov et al., 2005a; Chubanov et al., 
2007; Chubanov et al., 2006; Chubanov et al., 2005b; Chubanov et al., 2004; 
Schlingmann et al., 2007). TRPM6 gene encodes 7 isoforms via alternative splicing, with 
isoforms TRPM6a, TRPM6b, and TRPM6c containing the transmembrane channel 
domain and the kinase domain, isoforms TRPM6-kinase-1, -2, and -3 containing only the 
kinase domain, and the testes-specific isoform TRPM6t containing only the 
transmembrane domain (Chubanov et al., 2004). Hetero-tetramer channel complexes 
formed between TRPM6 and TRPM7 and homo-tetrameric TRPM7 channels are active 
and are responsible for magnesium ion transportation (Chubanov et al., 2005b; Chubanov 
et al., 2004; Schlingmann et al., 2007), while homo-tetramer channels formed by TRPM6 
alone are not functional (Zhang et al., 2014).  
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TRPM7 is ubiquitously expressed in all tissue types, whereas the expression of 
TRPM6 is regulated during development and is eventually confined to a few tissue types 
(Chubanov et al., 2005a; Walder et al., 2009). TRPM6 has been reported to play a role 
during embryonic development and in embryonic stem cell maintenance: TRPM6-
knockout in mouse caused embryonic mortality and neural tube defects (Walder et al., 
2009); homozygous TRPM7-deficient mice were also embryonic lethal, while mouse 
embryonic stem cells deficient in TRPM7 displayed growth arrest which could be 
rescued by Mg2+ supplementation (Ryazanova et al., 2010). 
 
In the second part of this study I report that using target identification techniques 
followed by functional validations, I identified TRPM6 as the biological target of MEG. 
Using a magnesium sensor I demonstrated that MEG effectively reduces cellular 
magnesium level. I also showed that both inhibition of the magnesium-importing activity 
of TRPM6/TRPM7 channel complex by known channel blockers and withdrawal of Mg2+ 
in the differentiation medium gave rise to similar phenotypes as compared to MEG 
treatment. These data suggest that MEG may exert its biological function by acting as an 
inhibitor of TRPM6/TRPM7 channel activity and, subsequently, by modulating cellular 
Mg2+ uptake. This study uncovers a novel molecular mechanism which governs early 
mesoderm and DE inductions through regulation of magnesium homeostasis. 
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Results 
Small scale chemical screening identified a novel small molecule that induces mesoderm 
and endoderm, but not neural differentiation of hESCs 
In Chapter 2 I described the identification of 29 bioactive small molecules that 
potently disrupt hESC pluripotency. Using this compound collection I conducted a screen 
(Materials and Methods) to search for small molecules that specifically induce mesoderm 
and DE differentiations, and identified compound 6528694 (N-({[2-chloro-5-
(trifluoromethyl)phenyl]amino}carbonothioyl)-4-isopropylbenzamide; Figure 3.1A). A 7-
day treatment of 6528694 in human embryonic stem cells (hESCs) maintained under a 
pluripotency culture condition ("mTeSR1" condition hereafter) (Ludwig et al., 2006) 
induced elevated protein expressions of mesoderm markers T (Brachuary) and EOMES 
(Eomesodermin) and DE markers SOX17 and FOXA2, but not neural-specific markers 
PAX6 and SOX1 (Figure 3.1B). Meanwhile pluripotency was disrupted as expected, 
shown by downregulations of the pluripotency markers OCT4 and SOX2 (Figure 3.1B). 
To further confirm its selectivity against the neural lineage, I incubated 6528694 with 
hESCs undergoing neural differentiation driven by a BMP pathway inhibitor 
Dorsomorphin (Kim et al., 2010; Mak et al., 2012; Zhou et al., 2010b) (Materials and 
Methods). Addition of 6528694 completely abolished the neural induction effect of 
Dorsomorphin, as demonstrated by the failure of induction for SOX1 and PAX6 (Figure 
3.1C). I thus name this compound Mesendogen, short for Mesoderm and Definitive 
Endoderm Inducing Reagent, and hereafter refer to this molecule as MEG for short.  
 
The sole fact that lineage-specific markers were elevated upon MEG treatment 
cannot prove that mesoderm or DE progenitors have been successfully generated. To 
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prove the existence of such a population, one must demonstrate the emergence of a 
distinct cell population that expresses progenitor markers at the single cell level. 
However, MEG treatment alone was insufficient to induce such a distinct mesoderm 
progenitor population: when incubated with hESCs in a growth factor-free mesoderm 
basal differentiation medium (Materials and Methods), MEG marginally increased T 
expression in the overall population, but failed to drive the differentiation of a distinct T+ 
population compared to the DMSO control, as shown by FACS analysis (Figure 3.2). I 
thus decided to test whether MEG could enhance the efficiencies of growth factor-guided 
mesoderm and DE differentiation protocols at generating mesoderm and DE progenitors.  
 
MEG induces nearly homogeneous mesoderm differentiation in combination with growth 
factors 
To test the effect of MEG in growth factor-induced mesoderm differentiation, I 
first derived a 2-dimensional (2-D) growth factor-guided mesoderm induction protocol 
(Figure 3.3 and Materials and Methods; "A-BVF" method hereafter) modified based on 
previous publications (Bernardo et al., 2011; Evseenko et al., 2010; Yu et al., 2011). 
Briefly, Activin A (A), bone morphogenetic protein 4 (BMP4; B), vascular endothelial 
growth factor (VEGF; V), and basic firoblast growth factor (bFGF; F) were used to drive 
differentiation; cells were analyzed after 1.5 - 2 days of induction. Using this method, I 
found that mesoderm differentiation efficiencies highly depended on the initial plating 
densities of hESCs: the lowest plating density tested (0.1 × 105 cells/cm2) gave the 
highest yield of T+EOMES+ cells (73.1±3.2% by FACS; Figure 3.4) which represent 
mesoderm progenitors; this efficiency quickly dropped to near-zero at and above 0.5 × 
105 cells/cm2 (Figure 3.4).  
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I then added MEG to the A-BVF induction protocol, either by directly combining 
with the growth factors (Figure 3.3; "MEG+A-BVF" or "combination" condition 
hereafter) or by pre-incubating in mTeSR1 medium for 24 hours before starting the 
growth factor treatments (Figure 3.3; "MEG->A-BVF" or "pre-treatment" condition 
hereafter). Both approaches dramatically improved the induction efficiencies of A-BVF 
in all plating densities tested (Figure 3.4). Most notably, the combination condition 
enhanced the differentiation efficiency (measured by percentage of T+/EOMES+ cells) at 
the density of 0.1 × 105 cells/cm2 from 73.1±3.2% for the A-BVF condition to an average 
of 82.7±3.6%, whereas the pre-treatment condition dramatically enhanced the efficiency 
at 0.25 × 105 cells/cm2 from 25.8±10.3% to 86.1±1.3% (Figure 3.4). An example of 
nearly homogeneous mesoderm differentiation at 0.25 × 105 cells/cm2 plating density 
under both the pre-treatment condition and the combination condition is shown in Figure 
3.5. Similar results were acquired through immunofluorescence staining (Figure 3.6) and 
Western blotting (Figure 3.7) using the same markers T and EOMES, and through qPCR 
using a range of mesoderm markers including T, EOMES, MIXL1, EVX1, TBX6, HAND1, 
MESP1, and MEOX1 (Figure 3.8).  
 
MEG induces nearly homogeneous definitive endoderm differentiation in combination 
with growth factors 
To test whether MEG enhances growth factor-induced DE differentiation in a 
similar fashion as compared to its effects in mesoderm differentiation, I first established a 
2-D growth factor-guided DE induction protocol (Figure 3.9 and Materials and Methods; 
"AWS" method hereafter) designed based on reported methods (Borowiak et al., 2009b; 
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D'Amour et al., 2005) with modifications. Briefly, Activin A (A), WNT3A (W), and 
increasing concentrations of fetal bovine serum (S) were applied to drive differentiation; 
cells were analyzed after 5 - 7 days of induction. Using this method I found that, similar 
to mesoderm differentiation, DE differentiation efficiencies also highly depended upon 
the initial plating densities, as lower densities again gave rise to higher differentiation 
efficiencies as measured by percentage of SOX17+FOXA2+ cells which represent DE 
progenitors, using FACS analysis (Figure 3.10). The highest differentiation efficiencies 
induced by the AWS condition were given by cells plated at 0.25 × 105 cells/cm2 
(40.6±30.2%; Figure 3.10). 
 
I then added MEG to the AWS condition either by pre-treatment (Figure 3.9; 
"MEG->AWS" or "pre-treatment" condition) or in combination with the growth factors 
(Figure 3.9; "MEG+AWS" or "combination" condition). Both approaches significantly 
boosted differentiation efficiencies for all plating densities tested (Figure 3.10). Most 
notably, both treatments dramatically enhanced the differentiation efficiency at the 
density of 1.0 × 105 cells/cm2, from 11.8±8.7% SOX17+FOXA2+ for the AWS condition, 
to an average of 72.7±19.7%  for the combination condition and 87.7±7.6% for the pre-
treatment condition (Figure 3.10). In some experiments, MEG treatments dramatically 
enhanced the efficiencies of DE progenitor differentiation to >90% under this optimum 
plating density, as shown by FACS analysis (Figure 3.11). A time course analysis of the 
MEG->AWS condition by immunofluorescence staining of SOX17 and FOXA2 is shown 
in Figure 3.12, also demonstrating a nearly homogeneous SOX17+FOXA2+ culture on 
day 7. The expressions of several other endoderm-specific markers including CER1, 
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GATA4, GATA6, and GSC were also significantly enhanced by MEG, as shown by 
Western blotting (Figure 3.13) and qPCR (Figure 3.14). It should be noted that SOX17, 
FOXA2, and all the other endoderm markers discussed so far are pan-endoderm markers 
that are expressed in both definitive and extra-embryonic endoderm lineages (Borowiak 
et al., 2009b). In order to rule out the possibility of extra-embryonic endoderm (ExEn) 
differentiation in this method, I examined the expressions of ExEn-specific markers AFP 
(-fetoprotein) and SOX7 using Western blotting (Figure 3.13) and qPCR (Figure 3.14). 
Results showed no significant elevation of AFP and SOX7 in all differentiation 
conditions examined (Figures 3.13 and 3.14), verifying the DE-lineage identity of the 
differentiated progenies.  
 
I find one technical question particularly worth noting for the FACS analyses 
conducted in this study, which is that undifferentiated hESCs already possess significant 
background signals for T, EOMES, SOX17, and FOXA2 stainings before undergoing 
differentiations. Therefore, if isotype controls were used to set up quadrants for the dot 
plots, these background signals will lead to extremely high false positive rates for both 
mesoderm (98.42% T+EOMES+; Figure 3.15) and DE (46.74% SOX17+FOXA2+; Figure 
3.16) differentiations. Thus, undifferentiated hESCs stained with T and EOMES 
antibodies (for mesoderm differentiation experiments) or with SOX17 and FOXA2 
antibodies (for definitive endoderm differentiation experiments), instead of isotype IgG 
controls, were used as gating controls for all FACS analyses performed in this study to 
ensure a stringent measurement of the differentiation efficiencies.  
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MEG possesses robust differentiation-enhancing activities to human induced pluripotent 
stem cells (hiPSCs) and to hESCs under various mesoderm and DE differentiation 
conditions 
The differentiation-enhancing effects of MEG are robust and are not limited to 
hESCs or to the above mentioned A-BVF and AWS differentiation conditions. The first 
point is evidenced by the fact that MEG effectively enhanced the mesoderm 
differentiation efficiency of a human induced pluripotent stem cell (hiPSC) line MMW2 
(Mali et al., 2010) in a similar fashion as compared to its effect in hESCs (Figure 3.17). A 
DE differentiation-enhancing effect of MEG similar to what was found in hESCs was 
also observed in the hiPSC line MMW2 (Figure 3.18). 
 
MEG also improved the efficiencies of several variations of mesoderm and DE 
induction conditions adopted from reported methods with modifications, including  BVF 
(Bernardo et al., 2011) (BMP4, VEGF, and bFGF; Figure 3.19A) and BF (Bernardo et al., 
2011; Yu et al., 2011) (BMP4 and bFGF; Figure 3.19B) conditions for mesoderm 
differentiation, and AW-B27 (Norrman et al., 2013) (serum replaced by B-27 supplement; 
Figure 3.20A), AW-ITS (Cai et al., 2007) (serum replaced by ITS supplement; Figure 
3.20B), and AS (Borowiak et al., 2009b) (withdrawal of WNT3A; Figure 3.20C) 
conditions for DE differentiation, demonstrating that MEG possesses general mesoderm 
and DE differentiation-enhancing activities that are not confined to the A-BVF and AWS 
conditions used in this study. Detailed protocols for these variant differentiation 
conditions are described in Materials and Methods.  
 
 
75 
 
Delayed treatments of MEG (initiate on day 1 rather than on day 0) were ineffective 
Based on the results that the pre-treatment conditions of MEG in both mesoderm 
and DE differentiations gave rise to similar, if not better, differentiation efficiencies 
compared to the combination conditions, I hypothesized that MEG may function by 
triggering a pathway (or pathways) involved only in the very early phases of mesoderm 
and DE inductions. Indeed, for both MEG+A-BVF and MEG+AWS conditions, the 
differentiation-enhancing effects of MEG were nearly completely lost when MEG was 
added starting from day 1 of differentiation instead of from day 0 (Figures 3.21A and 
3.21B), strongly supporting this hypothesis.  
 
In vitro kinome screen and functional validations identified TRPM6 as the biological 
target of MEG 
To investigate the molecular mechanism of MEG, I employed target identification 
techniques (Schenone et al., 2013; Ziegler et al., 2013). The enzymatic activities of 
kinases are typically inhibited at their ATP-binding sites by small planar compounds with 
no stereocenters and high aromatic contents (Huigens et al., 2013). Due to the planar 
structure and the lack of stereocenters of the MEG molecule, I postulated that MEG 
might function by inhibiting proteins containing ATP-binding sites, such as kinases. I 
thus applied an in vitro kinase screen using a commercial service named KINOMEscan 
(DiscoveRx; Materials and Methods). A total of 456 kinases were analyzed, with results 
summarized in Figure 3.22A: lower Percent-of-Control (%Ctrl) values indicate stronger 
interactions between the test compound and the kinases. Only two kinases gave %Ctrl 
values lower than 60, with %Ctrl values of 50 for TRPM6 and 47 for NEK3 (Figure 
3.22B). 
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A previous study showed that TRPM6-knockout mouse demonstrated 
developmental defects in neural tube formation (Walder et al., 2009), indicating a 
potential involvement of TRPM6 in the regulation of early embryonic development. I 
thus hypothesized that TRPM6 may be the biological target of MEG. 
 
To test this hypothesis I first confirmed the expression of TRPM6 in 
undifferentiated hESCs. Indeed, RT-PCR analysis using TRPM6 isoform-specific 
primers (Chubanov et al., 2004) showed that the kinase- and channel domain-containing 
isoforms TRPM6a and TRPM6b, but not the other isoforms of TRPM6, were expressed 
in undifferentiated hESCs (Figure 3.23). TRPM7, the ubiquitously expressed member of 
the TRPM protein family (Chubanov et al., 2005a), was also expressed in hESCs as 
expected (Figure 3.23).  
 
I then tested whether the inhibition of TRPM6 expression can mimic the effect of 
MEG on hESC differentiation. Indeed, TRPM6 knockdown significantly enhanced 
growth factor-induced mesoderm differentiation to an extent comparable to MEG-
induction, as measured by the percentage of T+EOMES+ mesoderm progenitor cells in 
differentiated cultures (Figure 3.24). TRPM6 knockdown also gave similar enhancement 
effects to the growth factor-induced DE differentiation with the efficiencies measured by 
percentage of SOX17+FOXA2+ DE progenitor cells (Figure 3.25). On the other hand, 
knockdown of NEK3 failed to offer any consistent enhancement effect during growth 
factor-induced mesoderm (Figure 3.26A) and DE differentiations (Figure 3.26B). The 
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shRNA constructs of TRPM6 and NEK3 were delivered to cells via transient transfection 
at the onset of differentiation in order to avoid the possibility that stable knockdown by 
lentiviral delivery may affect the survivability of the infected cells, leading to the 
selective loss of infected cells by the end of a differentiation cycle and thus inaccurate 
measurement of the differentiation efficiency (Materials and Methods). These results, 
from a phenotypical standpoint, confirmed that TRPM6, but not NEK3, is more likely to 
be the biological target of MEG. 
 
Inhibitions of TRPM6/TRPM7 channel activity and cellular Mg2+ uptake mimic the 
biological effect of MEG 
As the best understood biological function of TRPM6 is in magnesium ion 
transportation (Chubanov et al., 2005b; Chubanov et al., 2004; Schlingmann et al., 2007), 
I set out to investigate the effect of MEG on cellular magnesium homeostasis. Indeed, 
overnight incubation of MEG dramatically decreased intracellular magnesium level in a 
dose dependent manner, as shown by flow cytometry analysis using a magnesium sensor 
Mag-fluo-4 as indicator (Figure 3.27). I thus hypothesized that MEG functions by 
inhibiting the magnesium transport activity of TRPM6/TRPM7 channel, and tested this 
hypothesis by examining whether other known TRPM6/TRPM7 channel blockers or 
Mg2+-withdrawal can phenocopy MEG. 
 
The addition of TRPM6/TRPM7 channel blockers Rethenium Red (50 M) and 
2-APB (50 M) indeed significantly enhanced mesoderm differentiation efficiency to the 
same degree as observed in MEG induction (10 M) (Figure 3.28); similar results were 
obtained in DE differentiation with 2-APB at 50 M and Rethenium Red at 10 M 
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(Figure 3.29). Meanwhile, withdrawal of Mg2+ in mesoderm differentiation medium 
dramatically enhanced growth factor-induced mesoderm differentiation to a degree even 
greater than that achieved by MEG treatment (74.3% versus 42.1% T+EOMES+; Figure 
3.30), whereas the combined treatment of MEG failed to further enhance mesoderm 
differentiation efficiency on top of Mg2+-withdrawal (73.4% versus 74.3% T+EOMES+; 
Figure 3.30), indicating that withdrawal of Mg2+ not only phenocopied MEG but also 
rendered MEG-treatment ineffective for further mesodermal induction. Similar results 
were observed in DE differentiation, with Mg2+-withdrawal during the first day of 
differentiation significantly boosted the overall efficiency from 49.8% to 75.9% 
SOX17+FOXA2+ (Figure 3.31). Taken together, these results demonstrate that MEG most 
likely exerts its biological function by inhibiting the TRPM6/TRPM7 channel activity 
and, subsequently, cellular magnesium homeostasis. 
 
Discussion 
In summary, this study demonstrates nearly homogeneous derivations of 
mesoderm and DE progenitors from hPSCs enhanced by a novel small molecule inhibitor 
MEG. Further investigation indicates that MEG performs its biological function by 
targeting TRPM6 and subsequently regulating cellular magnesium level.  
 
Extensive efforts were taken to scrutinize the identities of the differentiated 
progenies and to ensure accurate measurements of the differentiation efficiencies in this 
study. This includes the applications of multiple experimental methods such as FACS 
analysis, immunofluorescence staining, Western blotting, and quantitative PCR. Most 
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notably, the method of intracellular FACS staining of lineage-specific markers, arguably 
one of the most accurate and discriminative method currently available for cell-fate 
validation at the single cell level, was used as the primary method in this study to 
distinguish and quantify the productions of mesoderm and DE progenitors.  
 
The fact that MEG, TRPM6/TRPM7 channel blockers, and magnesium-
withdrawal simultaneously enhanced the inductions of both mesoderm and DE, the two 
daughter lineages of primitive streak (or mesendoderm), indicates that a low intracellular 
level of magnesium may be favorable to primitive streak formation during early human 
development. The fact that delayed treatment of MEG was ineffective also indicates that 
this biological phenomenon may be most relevant at the earliest onset of primitive streak 
induction in vivo. 
 
In summary, this study develops a robust and easily applied chemical tool for 
directed differentiation which could easily be routinely integrated into existing hPSC-
based differentiation protocols that aim at deriving mesoderm and DE lineage progenies. 
This study also identified TRPM6 as the endogenous protein target of the small molecule 
MEG, which in turn shed light to a potentially novel function of magnesium during early 
human development, especially germ layer specification. Last but not least, as a potential 
chemical inhibitor of TRPM6/TRPM7 channel complex, the discovery of MEG could 
provide the scientific community with a novel tool for the basic research of 
TRPM6/TRPM7 channel complex or a novel drug candidate for diseases associated with 
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abnormal TRPM6/TRPM7 channel activities and magnesium homeostasis (Nair et al., 
2012; Swaminathan, 2003; Wolf and Trapani, 2012). 
 
Materials and Methods 
Cell culture 
H9 and H1 hESC lines (WiCell Research Institute, Madison, WI) and MMW2 
hiPSCs (Mali et al., 2010) were maintained under a feeder condition or a feeder-
independent condition. For the feeder condition (Thomson et al., 1998), primary mouse 
embryonic fibroblasts (MEFs) prepared from embryos of pregnant CF-1 mice (day 13.5 
of gestation; Charles River) were cultured in DMEM containing 10% FBS (Hyclone), 1% 
non-essential amino acids (NEAA; Invitrogen), and penicillin/streptomycin, and 
mitotically inactivated by gamma irradiation. H9 and H1 hESCs and hiPSCs were 
cultured on irradiated MEFs in media containing DMEM/F12, 20% knockout serum 
replacement (KSR; Invitrogen), 4 ng/ml basic fibroblast growth factor (bFGF; 
Invitrogen), 1% NEAA, 1 mM glutamine, and 0.1 mM β-mercaptoethanol. For the 
feeder-independent condition, hESCs and hiPSCs were cultured on Matrigel (BD 
Biosciences)-coated plates in mTeSR1 medium (StemCell Technologies) as described 
(Ludwig et al., 2006). Experiments described in this study were conducted with H9 and 
H1 hESCs between passages 30 and 60.  
 
Small scale screening of mesoderm and DE inducers 
For this screen, hESCs were maintained in the pluripotent state in mTeSR1 
medium (Ludwig et al., 2006). Small molecules were added and incubated for 5 - 7 days 
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to induce differentiation. Differentiated cultures were then assayed for mesoderm, DE, 
and neural lineage-specific marker expressions using Western blotting. Compounds that 
selectively induced the expressions of mesoderm and DE markers, but not neural markers, 
were identified as hits. 
 
Neural differentiation 
For neural differentiation hESCs were dissociated by Accutase (Invitrogen) and 
seeded onto culture plates pre-coated with Matrigel (BD Biosciences) in mTeSR1 
medium (StemCell Technologies) supplemented with Y-27632 (10 μM; Calbiochem). 
Cultures were let grow till complete confluency and then changed into neural induction 
medium composed of Advanced DMEM/F12, 1% N-2 supplement, and Glutamax (all 
from Invitrogen) and supplemented with or without Dorsomorphin (1 μM; Sigma). 
Medium was changed every day. Cells were collected on day 8 for analysis. 
 
Mesoderm differentiation 
To induce directed mesoderm differentiation, we used a growth-factor 
combination (“A-BVF”), as previously reported with modifications (Bernardo et al., 2011; 
Evseenko et al., 2010; Yu et al., 2011). H1 and H9 hESCs or MMW2 hiPSCs were 
dissociated by Accutase (Invitrogen) and seeded onto culture plates pre-coated with 
Matrigel (BD Biosciences) in mTeSR1 medium (StemCell Technologies) supplemented 
with Y-27632 (10 μM; Calbiochem). The day of seeding was referred to as “day -2”. On 
day 0, mTeSR1 medium was replaced by a mesoderm induction medium, in which the 
basal medium (Advanced RPMI-1640 basal medium supplemented with B-27 and 
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Glutamax; all from Invitrogen) was supplemented by Activin A (R&D Systems), BMP4 
(Invitrogen), human VEGF (Invitrogen), and bFGF (Invitrogen) (all at 10 ng/ml) from 
day 0 to day 1, while Activin A was removed from this medium from day 1 to day 2. This 
protocol was referred to as the A-BVF condition.  
 
For MEG induction, MEG was either added to the mTeSR1 medium on day “-1” 
as the “MEG->A-BVF” or “pre-treatment” condition (10 μM), or added to the mesoderm 
induction medium as the “MEG+A-BVF” or “combination” condition (1, 5, or 10 μM). 
Cells were collected on day 1.5 to day 2 of this protocol for further analyses. 
 
Variations of mesoderm induction protocols used in this study include the “BVF” 
condition with BMP4 (10 ng/ml), VEGF (10 ng/ml), and bFGF (20 ng/ml), and the “BF” 
condition with BMP4 (10 ng/ml) and bFGF (20 ng/ml).  
 
Definitive endoderm differentiation 
To induce definitive endoderm differentiation, we applied a method utilizing 
Activin A, WNT3A and low concentrations of fetal bovine serum (FBS) which was 
modified from previously reported methods (Borowiak et al., 2009b; D'Amour et al., 
2005). H1 and H9 hESCs or MMW2 hiPSCs were seeded in the same way as described 
for mesoderm differentiation, on day “-2”. On day 0, mTeSR1 medium was replaced by 
an definitive endoderm induction medium, in which a basal medium (Advanced RPMI-
1640 medium supplemented by Glutamax; Invitrogen) was supplemented by Activin A 
(50 or 100 ng/ml; from day 0 to day 7), WNT3A (25 ng/ml; from day 0 to day 1) (R&D 
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Systems), 0.2% FBS (from day 1 to day 2), and 2% FBS (from day 2 to day 7). This 
protocol was referred to as the AWS condition. 
 
For MEG induction, MEG was either added to the mTeSR1 medium at 10 μM on 
day “-1” as the “MEG->AWS” or “pre-treatment” condition, or added to the definitive 
endoderm induction medium at 1 μM throughout the course of differentiation as the 
“MEG+AWS” or “combination” condition. Cells were collected on day 5 of this protocol 
for qPCR analysis, and day 7 for Western blotting or FACS analysis. 
 
Variations of DE induction protocols used in this study include the “AW-B27” 
condition in which FBS was replaced by 2% B-27 supplement (Invitrogen), the “AW-ITS” 
condition in which FBS was replaced by Insulin-Transferrin-Selenium supplement (ITS; 
Invitrogen) at concentrations of 0.1% from day 1 to day 2 and 1% from day 2 to day 7, 
and the “AS” condition in which WNT3A was removed from the growth factor 
combination. 
 
Flow cytometry  
Single cell suspensions were acquired through Accutase (Invitrogen) treatment. 
Cells were fixed and stained using the Transcription Factor Buffer Set (BD Biosciences) 
following the manufacturer’s instructions. Conjugated antibodies were used, including T-
PE, EOMES-APC, FOXA2-Alexa488, and SOX17-APC (all from R&D Systems). Cells 
were resuspended in PBS supplemented with 1% BSA and analyzed using a BD 
Biosciences LSR II flow cytometry analyzer and BD FACSDiva software.  
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Undifferentiated cells cultured in mTeSR1 medium and stained with T and 
EOMES antibodies (for mesoderm) or SOX17 and FOXA2 antibodies (for definitive 
endoderm), instead of isotype IgG controls, were used as gating controls. This is due to 
the fact that undifferentiated hESCs already possess significant background signals for T, 
EOMES, SOX17, and FOXA2 staining before undergoing mesoderm or DE 
differentiations. If isotype controls were used to set up quadrants, these background 
signals will lead to extremely high false positive rates for both mesoderm (98.42% 
T+EOMES+; Figure 3.15) and DE (46.74% SOX17+FOXA2+; Figure 3.16) 
differentiations. 
 
Western blotting 
Cultured cells were lysed directly by 2× Laemmli buffer (Bio-Rad), boiled for 5 
min, and analyzed using SDS-PAGE electrophoresis followed by wet-transfer onto 
nitrocellulose membranes using a system manufactured by Bio-Rad. The membranes 
were blocked using blocking solution (5% BSA in Tris-buffered saline containing 0.1% 
Tween-20 [TBST]), and then incubated with primary antibodies, diluted in TBST, at 4°C 
overnight. The membranes were then washed by TBST for 3 × 5 min, and incubated with 
horse radish peroxidase (HRP) conjugated secondary antibodies at room temperature for 
1 hr. Finally, the membranes were washed 3 - 5 × 5 min by TBST and developed using 
Super-Signal West Pico Chemiluminescent Substrate (Pierce).  
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Immunofluorescent staining 
Cells were washed once with phosphate-buffered saline (PBS) and fixed by 4% 
paraformaldahyde (Santa Cruz) at room temperature for 20 min, permeabilized by 0.5% 
Triton X-100 (Sigma) in PBS (PBST) for 15 min, and then blocked with 5% donkey 
serum (Sigma) in 0.1% PBST at room temperature for 1 hr. The samples were incubated 
with primary antibodies in 0.1% PBST at 4°C overnight, washed three times by PBS, and 
then incubated with fluorescent-labeled secondary antibodies in 0.1% PBST at room 
temperature for 2 hr. Finally, the cells were incubated with DAPI for 5 min, washed three 
times by PBS, and subjected to fluorescent microscopy analysis (Zeiss). 
 
RNA extraction, reverse transcription, and quantitative-PCR 
Total RNA were isolated using RNeasy mini kit (QIAGEN). cDNAs were 
synthesized from the purified RNAs using Reverse Transcription System (Promega). 
Quantitative-PCR was performed using QuantiTech SYBR Green PCR kit (QIAGEN). 
Signals were analyzed using the comparative CT method, and ACTB gene was used as an 
internal control.  
 
For TRPM6 isoform detection, cDNAs extracted from undifferentiated hESCs 
were used as templates for PCR amplification of the isoforms followed by agarose gel 
electrophoresis. For the sequences of isoform-specific PCR primers see Chubanov et al 
(Chubanov et al., 2004).  
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KINOMEscan (DiscoveRx) 
In this screen, DNA-tagged recombinant kinases were bound by ligands linked to 
a solid support. When a small molecule inhibitor was added, it will bind to its target 
kinase(s), either at the ligand-binding sites which directly competes with the ligand, or at 
other parts of the protein which indirectly inhibits ligand-binding of the kinase by 
inducing conformational changes. This inhibition will release the target kinase of this 
small molecule from its ligand, and kinases released from the solid support will be 
detected by PCR analysis through their DNA tags. Results for binding interactions were 
reported as Percent of Control (%Ctrl): %Ctrl = [(positive control signal – test compound 
signal) / (positive control signal – negative control signal)] × 100. DMSO was used as 
negative control. Lower values of %Ctrl indicate stronger interactions between the test 
compound and the kinases. 
 
Fugene HD transfection 
Fugene HD reagent was purchased from Promega. Transfections were conducted 
following manufacturer’s instructions. Briefly, plasmid DNA and Fugene HD 
transfection reagent were mixed at a 3:1 ratio in Opti-MEM medium (Invitrogen), 
incubated 15 min at room temperature, and applied to cells at day -1 or day 0 of the A-
BVF or AWS differentiation protocols. ROCK inhibitor Y-27632 was added during 
transfection to boost transfection efficiency as previously reported (Yen et al., 2014). 
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Intracellular magnesium analysis 
The cell permeant magnesium ion sensor Mag-fluo-4 was purchased from 
Invitrogen. 10 M Mag-fluo-4 was loaded into cells for 30 min at room temperature in 
the dark, washed with PBS, and then analyzed using a BD Biosciences LSR II flow 
cytometry analyzer and BD FACSDiva software.  
 
Statistical analysis 
Statistical analyses were performed using Microsoft Excel. 
 F
F
d
c
S
a
o

m
6
c
igures 
igure 3.1. 
ifferentiat
ompound 6
OX17 and
nd PAX6, 
r treated w
-TUBULIN
arkers SO
528694 (M
ontrol.  
Compound
ion, but in
528694 (M
 FOXA2, m
and pluripo
ith 6528694
 was used
X1 and PA
EG, 10 M
 6528694 (
hibits neur
esendogen 
esoderm m
tency mark
 (MEG, 10
 as a loadin
X6 in H1 hE
) plus Dors
88
Mesendog
al different
or MEG). (
arkers T an
ers OCT4 a
 M) for 7 
g control. (C
SCs treate
omorphin f
 
en) induced
iation. (A)
B) Western
d EOMES, 
nd SOX2 in
days while 
) Western 
d with DMS
or 8 days. G
 mesoderm
 Chemical s
 blotting of
neural-spec
 H9 hESC
maintained 
blotting of 
O, Dorsom
APDH wa
 
 and endo
tructure of 
 endoderm m
ific marker
s untreated 
in mTeSR1
neural prog
orphin (1 
s used as a 
derm 
arkers 
s SOX1 
(mTeSR1) 
 medium. 
enitor 
M) and 
loading 
 F
p
h
igure 3.2. 
opulation 
ESCs treat
Mesendog
when appl
ed with DM
en (MEG) 
ied to a dif
SO and 5 
89
fails to indu
ferentiation
M MEG fo
 
ce a distin
 culture a
r 4 days. 
 
ct T+ meso
lone. FACS
derm prog
 analysis of
enitor 
 T in H9 
 F
s
igure 3.3. 
tudy.  
Schematic overviews 
90
of mesoder
 
m differentiation conditions used in this 
 F
c
s
d
c
–
igure 3.4. 
ombinatio
howing the
ifferentiati
onditions. 
 4 data poi
MEG indu
n with the 
 percentage
on of H9 an
Results from
nts were co
ces nearly 
A-BVF con
s of T+EOM
d H1 hESC
 six indepe
llected and 
91
homogeneo
dition: FA
ES+ popul
s under var
ndent expe
analyzed fo
 
us mesode
CS summa
ation acqui
ious plating
riments (n =
r each cond
 
rm differe
ry. Summa
red after 2 d
 densities a
 6) are sho
ition. 
ntiation in 
ry of FACS
ays of mes
nd differen
wn as mean
 results 
oderm 
tiation 
 ± SD; 3 
 F
c
H
B
igure 3.5. 
ombinatio
9 hESCs t
VF, and M
MEG indu
n with the 
reated with 
EG->A-BV
ces nearly 
A-BVF con
mesoderm 
F. Cells w
92
homogeneo
dition: FA
differentiat
ere plated a
 
us mesode
CS. FACS 
ion conditio
t 0.25 × 105
rm differe
analysis of 
ns includin
 cells/cm2. 
ntiation in 
T and EOM
g A-BVF, M
 
ES in 
EG+A-
 F
c
I
u
s
0
B
igure 3.6. 
ombinatio
mmunofluo
ndergo me
tained with
.75 × 105 c
VF condit
MEG indu
n with the 
rescent sta
soderm diff
 DAPI (blu
ells/cm2 for
ion. 
ces nearly 
A-BVF con
ining of T (
erentiation 
e). Cells we
 MEG+A-B
93
homogeneo
dition: im
red) and EO
for ~1.5 da
re plated at
VF conditi
 
us mesode
munofluor
MES (gree
ys under va
 0.25 × 105
on, and 1.0
rm differe
escent stain
n) in H1 hE
rious condit
 cells/cm2 fo
 × 105 cells/
 
ntiation in 
ing. 
SCs induce
ions. Nucle
r A-BVF c
cm2 for ME
d to 
i were 
ondition, 
G->A-
 F
c
E
B
g
T
igure 3.7. 
ombinatio
OMES in 
VF and M
rowth facto
UBULIN w
MEG indu
n with the 
H9 hESCs i
EG->A-BV
rs were use
as used as
ces nearly 
A-BVF con
nduced to u
F condition
d as a cont
 a loading c
94
homogeneo
dition: We
ndergo me
s. Cells cul
rol (Blank)
ontrol. 
 
us mesode
stern blott
soderm diff
tured in me
. Cells were
 
rm differe
ing. Wester
erentiation 
soderm bas
 plated at 1
ntiation in 
n blotting o
for 2 days u
al medium 
.0 × 105 cell
f T and 
nder A-
without 
s/cm2. -
 F
c
m
A
m
i
igure 3.8. 
ombinatio
esoderm m
ll values w
edium wit
ndependent
MEG indu
n with the 
arkers in H
ere normal
hout growth
 experimen
ces nearly 
A-BVF con
9 hESCs u
ized to the 
 factors. E
ts.  ACTB (
95
homogeneo
dition: qP
nder A-BV
mRNA leve
ach bar repr
-actin) wa
 
us mesode
CR. Quanti
F and MEG
l (=1) in ce
esents the m
s used as a 
rm differe
tative-PCR
+A-BVF co
lls cultured
ean ± SD 
loading con
 
ntiation in 
 analysis of
nditions fo
 in mesoder
(error bars)
trol. 
 
r 2 days. 
m basal 
. n = 2 
 F
u
igure 3.9. 
sed in this
Schematic
 study.  
 overviews 
96
of definitiv
 
e endoderm differentiation conditions 
 F
i
s
d
a
s
igure 3.10
n combina
howing the
efinitive en
nd differen
hown as m
. MEG ind
tion with th
 percentage
doderm dif
tiation cond
ean ± SD; 3
uces nearly
e AWS co
s of SOX17
ferentiation
itions. Res
 – 5 data po
97
 homogen
ndition: FA
+FOXA2+
 of H1 and
ults from si
ints were c
 
eous defini
CS summ
population 
 H9 hESCs 
x independe
ollected and
tive endode
ary. Summ
acquired aft
under vario
nt experim
 analyzed 
 
rm differe
ary of FAC
er 7 days o
us plating d
ents (n = 6)
for each con
ntiation 
S results 
f 
ensities 
 are 
dition. 
 F
i
F
i
c
igure 3.11
n combina
OXA2 in H
ncluding A
ells/cm2. 
. MEG ind
tion with th
1 hESCs t
WS, MEG+
uces nearly
e AWS co
reated with 
AWS, and 
98
 homogen
ndition: FA
definitive e
MEG->AW
 
eous defini
CS. FACS
ndoderm di
S for 7 day
tive endode
 analysis of
fferentiatio
s. Cells we
rm differe
 SOX17 an
n condition
re plated at
 
ntiation 
d 
s 
 1.0 × 105 
 F
i
I
u
a
igure 3.12
n combina
mmunofluo
ndergo def
nd 7 days. 
. MEG ind
tion with th
rescent sta
initive endo
Nuclei wer
uces nearly
e AWS co
ining of SO
derm differ
e stained wi
99
 homogen
ndition: im
X17 (red) a
entiation u
th DAPI (b
 
eous defini
munofluor
nd FOXA2
nder the ME
lue). Scale 
tive endode
escent stai
 (green) in H
G->AWS 
bar: 100 μm
 
rm differe
ning. 
9 hESCs i
condition fo
. 
ntiation 
nduced to 
r 1, 3, 
 F
i
S
d
c
×
a
l
igure 3.13
n combina
OX17, FO
ifferentiati
ultured in m
 105 cells/c
nd 1.5 × 10
oading con
. MEG ind
tion with th
XA2, CER
on under A
TeSR1 me
m2 for the 
5 cells/cm2
trol. 
uces nearly
e AWS co
1, and AFP 
WS, MEG+
dium were
AWS condi
 for the ME
100
 homogen
ndition: W
in H9 hESC
AWS, and 
 used as a c
tion, 1.0 × 
G->AWS c
 
eous defini
estern blot
s induced t
MEG->AW
ontrol (mTe
105 cells/cm
ondition. 
 
tive endode
ting. Weste
o undergo 
S condition
SR1). Cell
2 for the M
-TUBULIN
rm differe
rn blotting 
definitive en
s for 7 day
s were plate
EG+AWS c
 was used a
ntiation 
of 
doderm 
s. Cells 
d at 0.25 
ondition, 
s a 
 F
i
e
v
E
(
igure 3.14
n combina
ndoderm m
alues were
ach bar rep
-actin) wa
. MEG ind
tion with th
arkers in H
 normalized
resents the
s used as a
uces nearly
e AWS co
9 hESCs un
 to the mRN
 mean ± SD
 loading con
10
 homogen
ndition: qP
der AWS a
A level (=
 (error bars
trol. 
1 
eous defini
CR. Quant
nd MEG->
1) in cells c
). n = 2 ind
tive endode
itative-PCR
AWS cond
ultured in m
ependent ex
rm differe
 analysis o
itions for 5 
TeSR1 me
periments. 
ntiation 
f 
days. All 
dium. 
ACTB 
 F
c
A
E
a
u
u
s
igure 3.15
ombinatio
PC in H9 
OMES-AP
ntibodies c
sed as a ga
ndifferenti
ample). 
. MEG ind
n with the 
hESCs cultu
C antibodi
onjugated w
ting control
ated mTeSR
uces nearly
A-BVF con
red in mTe
es (T-PE/EO
ith the sam
, gave rise 
1 culture (
102
 homogen
dition: iso
SR1 mediu
MES-APC
e fluoropho
to a high pe
98.42% PE
 
eous mesod
type contro
m. Cells w
) or non-sp
res (isotyp
rcentage of
+APC+ in th
erm differ
l. FACS an
ere stained w
ecific IgG i
e control). I
 false-positi
e T-PE/EO
 
entiation in
alysis of PE
ith T-PE a
sotype cont
sotype IgG
ve cells in t
MES-APC 
 
 and 
nd 
rol 
, when 
he 
stained 
 F
i
a
A
I
I
p
A
igure 3.16
n combina
nd FOXA2
PC and FO
gG isotype
sotype IgG
ositive cell
lexa488+ i
. MEG ind
tion with th
 in H9 hES
XA2-Alex
 control ant
, when used
s in the und
n the SOX1
uces nearly
e AWS co
Cs cultured
a488 antibo
ibodies con
 as a gating
ifferentiate
7-APC/FO
103
 homogen
ndition: iso
 in mTeSR
dies (SOX
jugated wit
 control, ga
d mTeSR1 
XA2-Alexa
 
eous defini
type contr
1 medium. C
17-APC/FO
h the same 
ve rise to a
culture (~5
-488 staine
tive endode
ol. FACS a
ells were s
XA2-Alexa
fluorophore
 high percen
0% APC+/A
d sample). 
 
rm differe
nalysis of S
tained with
488) or non
s (isotype c
tage of fal
lexa488+ a
ntiation 
OX17 
 SOX17-
-specific 
ontrol). 
se-
nd ~98% 
 F
c
M
f
c
m
igure 3.17
ombinatio
MW2 hiP
or 2 days. C
onditions a
TeSR1 me
. MEG ind
n with the 
SCs differe
ells were p
nd 0.25  1
dium were
uces nearly
A-BVF con
ntiated in A
lated at 0.5
05 cells/cm
 used as a g
104
 homogen
dition: hiP
-BVF, ME
  105 cells/
2 for MEG+
ating contro
 
eous mesod
SC. FACS
G+A-BVF,
cm2 for A-B
A-BVF con
l. 
erm differ
 analysis of
 and MEG->
VF and M
dition. Cel
entiation in
 T and EOM
A-BVF co
EG->A-BV
ls cultured i
 
 
ES in 
nditions 
F 
n 
 F
i
F
u
M
igure 3.18
n combina
OXA2 in M
nder AWS
1.0  105 ce
EG->AW
. MEG ind
tion with th
MW2 hiP
, MEG+AW
lls/cm2 for 
S condition
uces nearly
e AWS co
SCs cells in
S, and ME
AWS and M
. Cells cultu
105
 homogen
ndition: hi
duced to un
G->AWS c
EG+AWS
red in mTe
 
eous defini
PSC. FACS
dergo defin
onditions fo
 conditions
SR1 mediu
tive endode
 analysis o
itive endod
r 7 days. C
, and at 0.5 
m were use
rm differe
f SOX17 an
erm differe
ells were p
 105 cells/
d as a gatin
 
ntiation 
d 
ntiation 
lated at 
cm2 for 
g control. 
 F
c
o
n
F
(
igure 3.19
ombinatio
f T in H1 h
g/ml) (BV
ACS analy
BF conditio
. MEG ind
n with the 
ESCs diffe
F condition
sis of T in 
n) for 1.5 d
uces nearly
A-BVF con
rentiated in
) for 1.5 day
H1 hESCs d
ays, with o
106
 homogen
dition: BV
 BMP4 (10 
s, with or w
ifferentiate
r without M
 
eous mesod
F and BF 
ng/ml), VE
ithout ME
d in BMP4
EG pre-tre
erm differ
conditions.
GF (10 ng/
G (10 M) 
 (10 ng/ml)
atment. 
entiation in
 (A) FACS 
ml), and bF
pre-treatme
 and bFGF 
 
 
analysis 
GF (20 
nt. (B) 
(20 ng/ml) 
 F
i
a
d
B
u
M
u
F
e
M
igure 3.20
n combina
nalysis of S
ifferentiati
27-supplem
105 cells/cm
ndergo def
EG->AW
sed in thes
ACS analy
ndoderm d
EG->AS 
. MEG ind
tion with th
OX17 and
on for 5 day
ent was u
2. (B) FAC
initive endo
-ITS condit
e condition
sis of SOX
ifferentiatio
condition w
uces nearly
e AWS co
 FOXA2 in
s in AW-B
sed in these
S analysis o
derm differ
ions. ITS- (
s instead of 
17 and FOX
n for 7 day
hich lacked
107
 homogen
ndition: va
 H9 hESCs 
27, MEG+A
 conditions 
f SOX17 a
entiation fo
insulin, tran
serum. Cel
A2 in H1 h
s in AWS c
 WNT3A. C
 
eous defini
riations of
induced to 
W-B27, an
instead of s
nd FOXA2 
r 5 days in
sferrin, and
ls were plat
ESCs indu
ondition, M
ells were p
tive endode
 the AWS c
undergo def
d MEG->A
erum. Cells
in H9 hESC
 AW-ITS, M
 selenium)
ed at 2.0  
ced to unde
EG->AWS
lated at 2.0
 
rm differe
ondition. (
initive end
W-B27 co
 were plate
s induced 
EG+AW-I
 supplemen
105 cells/cm
rgo definiti
 condition, 
  105 cells
ntiation 
A) FACS 
oderm 
nditions. 
d at 1.0  
to 
TS, and 
t was 
2. (C) 
ve 
and 
/cm2. 
 F
T
M
a
a
igure 3.21
 and EOM
EG+A-BV
nalysis of S
nd MEG+A
105 cells/cm
. Delayed M
ES in H9 h
F (with M
OX17 and
WS condit
2. 
EG treat
ESCs differ
EG added o
 FOXA2 in
ion with M
108
ment condi
entiated in 
n day 1 ins
 H1 hESCs 
EG added o
 
tions are in
MEG->A-B
tead of day 
differentiat
n day 0 or 
effective. (
VF, A-BV
0) conditio
ed for 7 day
day 1. Cells
A) FACS a
F, and delay
ns. (B) FAC
s in AWS c
 were plate
 
nalysis of 
ed 
S 
ondition 
d at 1.5  
 F
K
t
K
igure 3.22
INOMEsc
est compou
INOMEsc
. A kinome
an result. L
nd and the 
an. 
 screen ide
ower value
kinases. (B)
109
ntifies pote
s of %Ctrl i
 %Ctrl valu
 
ntial targe
ndicate stro
es for TRP
ts of MEG
nger interac
M6 and NE
 
. (A) Summ
tions betw
K3 as detec
ary of 
een the 
ted in 
 F
A
h
w
t
e
igure 3.23
garose gel
ESCs usin
here a ban
he band sho
xpression o
. TRPM6 i
 electropho
g TRPM6 is
d is suppos
wn in the “
f the t isofo
soforms ar
resis showi
oform-spec
ed to appea
t” lane is n
rm. 
110
e selectivel
ng RT-PCR
ific PCR p
r if the isofo
ot in the rig
 
y expressed
 amplificati
rimers. Whi
rm under d
ht position 
 in undiffe
on of undif
te arrowhea
etection is 
and thus do
 
rentiated h
ferentiated 
ds point to
present. No
es not indic
ESCs. 
H1 
 positions 
te that 
ate 
 F
d
T
d
igure 3.24
ifferentiat
RPM6 shR
ifferentiati
. TRPM6 k
ion. FACS 
NAs (1 - 4
on conditio
nock-dow
analysis of 
), and MEG
n (A-BVF c
11
n enhances
T and EOM
 (pre-treatm
ondition) fo
1 
 A-BVF-in
ES in H9 h
ent, 10 M
r 2 days. 
duced mes
ESCs treat
) under me
oderm 
ed with NT
soderm 
 
 shRNA, 
 F
a
s
igure 3.25
nalysis of S
hRNAs (1 
. TRPM6 k
OX17 and
- 4) under D
nock-dow
 FOXA2 in
E different
112
n enhances
 H1 hESCs 
iation cond
 
 AWS-indu
treated with
ition (AWS
ced DE di
 NT shRNA
 condition)
fferentiatio
 and TRPM
 for 7 days. 
 
n. FACS 
6 
 F
a
a
F
u
igure 3.26
nalysis of T
nd differen
OXA2 in H
nder AWS
. NEK3 kn
 and EOM
tiated unde
1 hESCs t
 condition f
ock-down 
ES in H1 h
r A-BVF co
ransfected w
or 7 days. 
113
shows no e
ESCs transf
ndition for
ith NT shR
 
ffect on dif
ected with 
 2 days. (B)
NA and N
ferentiatio
NT shRNA
 FACS anal
EK3 shRNA
n. (A) FAC
 and NEK3
ysis of SOX
s and diffe
 
S 
 shRNAs 
17 and 
rentiated 
 F
m
igure 3.27
agnesium 
. MEG red
sensor Mag
uces intrac
-fluo-4 in H
114
ellular ma
1 hESCs u
 
gnesium le
ntreated or 
vel. FACS 
treated with
analysis of 
 MEG ove
 
rnight.  
 F
B
o
A
igure 3.28
VF differ
r pre-treate
-BVF con
. TRPM6/T
entiation ef
d with ME
dition for 2
RPM7 ch
ficiency. F
G (10 M),
 days. 
115
annel block
ACS analys
 Ruthenium
 
ers phenoc
is of T and 
 Red (50 M
 
opy MEG
EOMES in
), and 2-A
 by enhanc
 H1 hESCs 
PB (50 M
ing A-
untreated 
) under 
 F
d
e
p
e
 
igure 3.29
ifferentiat
xperiments
anel) and D
ndoderm d
. TRPM6/T
ion efficien
 of H1 hES
MSO, ME
ifferentiatio
RPM7 ch
cy. FACS 
Cs pre-trea
G, and 10 
n condition
116
annel block
analysis of 
ted with DM
M Rutheni
 (AWS con
 
ers phenoc
SOX17 and
SO, 10 M
um Red (bo
dition) for 
opy MEG
 FOXA2 in
 MEG, and
ttom panel)
7 days. 
 
 by enhanc
 two indepe
 50 M 2-A
 under defi
ing AWS 
ndent 
PB (top 
nitive 
 F
A
t
M
 
igure 3.30
-BVF diff
reated with
g2+-free m
. Manipula
erentiation
 MEG (10 
edium for 
tions of M
. FACS ana
M) under A
2 days. 
117
g2+ level in
lysis of T a
-BVF diff
 
 culture me
nd EOMES
erentiation 
dium affec
 in H1 hES
condition in
t the effici
Cs untreate
 regular me
 
ency of 
d or 
dium or 
 F
e
d
 
 
igure 3.31
fficiency. F
ifferentiati
. Mg2+-with
ACS analy
on in AWS
drawal ph
sis of SOX
 condition, 
118
enocopies 
17 and FOX
using regul
 
MEG by e
A2 in H1 h
ar medium 
 
nhancing A
ESCs unde
or Mg2+-fre
WS differ
rgoing DE 
e medium, 
entiation 
for 7 days.
119 
 
Tables 
Antibody Source Catalog Number Dilution 
OCT4 Santa Cruz sc-9081 1:1,000 (WB) 
SOX2 Millipore AB5603 1:500 (WB) 
NANOG Cell Signaling 4903P 1:500 (WB) 
α-TUBULIN Abcam ab11304 1:10,000 (WB) 
GAPDH GeneScript A00192 1:10,000 (WB) 
T R&D systems AF2085 1:500 (WB/IF) 
EOMES Abcam ab23345 1:500 (WB/IF) 
SOX17 R&D systems AF1924 1:500 (WB/IF) 
FOXA2 Millipore 07-633 1:500 (WB/IF) 
CER1 Thermo-Pierce MA5-15554 1:500 (WB) 
AFP DAKO A0008 1:500 (WB) 
SOX1 R&D systems AF3369 1:500 (WB) 
PAX6 Covance PRB-278P 1:500 (WB) 
T-PE R&D Systems IC2085P 1:20 (FACS) 
EOMES-APC R&D Systems IC6166A 1:20 (FACS) 
FOXA2-
Alexa488 
R&D Systems IC2400G 1:40 (FACS) 
SOX17-APC R&D Systems IC1924A 1:20 (FACS) 
Goat IgG-PE 
isotype control 
R&D Systems IC108P 1:20 (FACS) 
Goat IgG-APC 
isotype control 
R&D Systems IC108A 1:20 (FACS) 
Mouse IgG2B-
APC isotype 
control 
BioLegend 400319 1:20 (FACS) 
Goat IgG-
Alexa488 isotype 
control 
R&D Systems IC108G 1:40 (FACS) 
 (WB: Western blotting; IF: immunofluorescence) 
 
Table 3.1. Antibody sources and dilutions 
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Primer Name Forward Primer (5'-3') Reverse Primer (5'-3') 
ACTB agagctacgagctgcctgac cgtggatgccacaggact 
OCT4-Isoform-A cttctcgccccctccaggt aaatagaacccccagggtgagc 
NANOG tttggaagctgctggggaag gatgggaggaggggagagga 
SOX2 ggcagctacagcatgatgcaggagc ctggtcatggagttgtactgcagg 
T (Brachyury) gctgtgacaggtacccaacc catgcaggtgagttgtcagaa 
EOMES gtggggaggtcgaggttc tgttctggaggtccatggtag 
MIXL1 ggcgtcagagtgggaaatcc gcagttcacatctacctcaagag 
EVX1 ttcacccgagagcagattg ccggttctggaaccacac 
TBX6 gaacggcagaaactgtaagagg gtgtgtctccgctcccatag 
HAND1 aaaggccctacttccagagc tgcgctgttaatgctctcag 
MEOX1 aaagtgtcccctgcattctg cactccagggttccacatct 
MESP1 ctgttggagacctggatgc cgtcagttgtcccttgtcac 
SOX17 acgccgagttgagcaaga tctgcctcctccacgaag 
FOXA2 tgggagcggtgaagatggaagggcac tcatgccagcgcccacgtacgacgac 
CER1 acagtgcccttcagccagact acaactactttttcacagccttcgt 
GSC gaggagaaagtggaggtctggtt ctctgatgaggaccgcttctg 
GATA4 ggaagcccaagaacctgaat gttgctggagttgctggaa 
GATA6 aatacttcccccacaacacaa ctctcccgcaccagtcat 
AFP agcttggtggtggatgaaac ccctcttcagcaaagcagac 
SOX7 ctcagggcagggaggtct gcactcggataaggagagtcc 
 
Table 3.2. Names and sequences of qPCR primers 
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Target shRNA Sequence (5’ – 3’) 
TRPM6 
TRPM6-1 ccggcctggcataaagaatgtatatctcgagatatacattctttatgccaggttttt 
TRPM6-2 ccggccctctaatctaaagcgagttctcgagaactcgctttagattagagggttttt 
TRPM6-3 ccggccaaattctaatggagtgtatctcgagatacactccattagaatttggttttt 
TRPM6-4 ccgggctccctatctgataactcaactcgagttgagttatcagatagggagcttttt 
NEK3 
NEK3-1 ccgggcagtcccatagaacagaaatctcgagatttctgttctatgggactgcttttt 
NEK3-2 ccggccttattatgtgcctccagaactcgagttctggaggcacataataaggttttt 
NEK3-3 ccggcgaagcataacacaccaagaactcgagttcttggtgtgttatgcttcgttttt 
 
Table 3.3. Names and sequences of shRNAs 
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CHAPTER 4: SPONTANEOUS SELF-ORGANIZATION OF A PRIMITIVE 
LYMPHATIC PLEXUS-LIKE STRUCTURE FROM HUMAN EMBRYONIC 
STEM CELLS TRIGGERED BY SMALL MOLECULES 
 
Abstract 
Human embryonic stem cells (hESCs), especially the emerging models of hESC-
derived self-organizing organoids, provide a potential platform for studying early human 
development and modeling human developmental disorders. However, previously 
reported organoid systems rely on pre-designed programs of external guidance to direct 
their differentiations, and were thus unable to reveal truly intrinsic developmental 
programs embedded in hESCs. Here I report two novel small molecules (Lymphgen 1/2) 
that trigger an unguided and spontaneous self-organizing event which gives rise to a 
balloon-like organoid structure. Gene expression analyses, functional assays, and 
morphological studies demonstrated that this self-organizing event recapitulates the in 
vivo human lymphatic morphogenesis program. Using this system, I unveiled the 
unguided emergence of a DiI-Ac-LDL+VE-cadherin+CD31+CD34+KDR+CD43- 
endothelial progenitor population, and identified a previously unknown VEGFR3+ 
progenitor population which may be responsible for human embryonic lymphatic 
development. This system provides a rare opportunity to visualize a truly spontaneous 
human developmental program in vitro.  
 
Introduction 
The mechanisms of organogenesis remain a central piece of the puzzle for human 
embryonic development. Traditional differentiation methods such as embryoid body (EB) 
formation (Itskovitz-Eldor et al., 2000a) and growth factor-directed 2-dimensional (2-D) 
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differentiations (Borowiak et al., 2009a) were unable to recapitulate 3-dimensional (3-D) 
self-organizing events during organogenesis. To solve this problem, the Yoshiki Sasai 
group pioneered the field of 3-D organoid self-organization by developing a series of 
conditions that guide hESCs into developmental programs mimicking various aspects of 
early human neurogenesis (Eiraku et al., 2011; Eiraku et al., 2008; Muguruma et al., 2010; 
Nakano et al., 2012; Sasai, 2013; Suga et al., 2011). Several groups later developed their 
own approaches for 3-D organoid-formation which recapitulated organogenesis events of 
organs originated from all three germ layers (Antonica et al., 2012; Cao et al., 2011; 
Lancaster et al., 2013; Mariani et al., 2012; Saito et al., 2011; Ueda et al., 2010; Wang 
and Ye, 2009; Xia et al., 2013). These studies all adopted a suspension culture system 
similar to that used for EB-formation. A different approach to organoid self-formation 
was later developed for the self-organization of intestine-like (McCracken et al., 2014; 
Spence et al., 2011; Wells and Spence, 2014) or kidney-like (Takasato et al., 2014) 3-D 
organoids that grew out of 2-D cultures. This "2-D" approach presents a unique 
advantage over the "3-D" approach in that it allows researchers to easily visualize and 
track the process of "sprouting", the formation of a 3-D luminal structure out of a 2-D 
epithelial sheet (Pohl et al., 2000), which is a vital process for a variety of organogenesis 
events such as vasculogenesis (Gerhardt, 2008), tracheal branching (Ghabrial and 
Krasnow, 2006), ureteric-bud branching (Basson et al., 2006), and breast development 
(Sternlicht, 2006). However, a major limitation of all reported self-organizing systems is 
that they all require continues guidance of external differentiation factors, such as growth 
factors, throughout their courses of differentiation, and are thus guided rather than truly 
spontaneous self-organizing processes. 
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A delicate state of balance exists between the pluripotency regulatory network 
and the differentiation regulatory pathways, and is required for the maintenance of 
pluripotency (Boyer et al., 2005; Shu et al., 2013). Disrupting this balanced state by 
altering the expressions or activities of different components that are important for the 
maintenance of this balance will trigger hESC differentiations in different ways. For 
example, inhibition of HSPA8 by a small molecule Displg causes un-directional 
differentiation (Chapter 2), whereas another small molecule MEG was shown to 
specifically enhance mesoderm and definitive endoderm differentiations (Chapter 3). I 
thus hypothesized that, by applying a stimulus that undermines this delicate balance in a 
certain way during the initial phase of differentiation, I may be able to trigger a truly 
spontaneous self-organizing event that can propagate on its own by following an intrinsic 
organogenesis program embedded in hESCs, without the need for any external guidance.  
 
The key to the success of this proposal is to find a proper stimulus that is able to 
trigger such a delicate differentiation event. Due to the unpredictable nature of this 
hypothesized mechanism of induction, a large number of highly diversified stimuli need 
to be tested in order for me to identify such a stimulus: no other method achieves this 
goal better than small molecule screening. Small molecules provide a source of 
practically inexhaustible structural diversity - a multitude of bioactive small molecules 
have been reported to modulate a large variety of biological molecules in various 
biological pathways - and are thus ideal candidate stimuli for my study. 
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Here I report the identification of two novel small molecules that trigger an 
unguided and spontaneous self-organization program during hESC differentiation, giving 
rise to a balloon-like 3-D organoid structure. This balloon-like structure was then 
identified as an in vitro counterpart of primitive lymphatic plexus which was the building 
blocks of embryonic lymphatic development in vivo, and the balloon-formation process 
was thus found to recapitulate lymphatic morphogenesis during human embryonic 
development. These two compounds were therefore named Lymphgen 1 and 2, 
respectively, for their properties as lymphatic-inducing reagents. Using this system I 
identified a spontaneously emerged population of DiI-Ac-LDL+VE-
cadherin+CD31+CD34+KDR+CD43- endothelial progenitor cells, discovered a previously 
uncharacterized VEGFR3+ progenitor population which may represent lymphatic 
progenitors responsible for human embryonic lymphatic development, and visualized the 
truly spontaneous progression of human lymphatic morphogenesis in vitro. 
 
Results 
Morphological screening identified two structurally similar compounds that induce a 
self-organizing balloon-like structure 
I previously conducted a high throughput screening (HTS) study and found 29 
bioactive small molecules that potently disrupt hESC pluripotency (Chapter 2). Using this 
compound collection I conducted a small-scale morphological screen (Figure 4.1 and 
Materials and Methods) to search for small molecules that can induce self-organization of 
3-D organoid structures. Briefly, hESCs were plated as 2-D cultures so that the 
emergence of any 3-D structures could be readily visible. Two consecutive phases were 
included in the screen: for the “induction phase”, small molecules were applied to hESCs 
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as the initial stimuli for periods long enough to induce differentiations; then for the 
“spontaneous self-organization phase”, the molecules were withdrawn, and the cultures 
allowed to go through self-driven differentiation processes in the hope that 3-D self-
organizing organoids may emerge from some of the cultures. Both phases were growth 
factor-free.  
 
Using this screen I identified two structurally similar compounds 5373471 and 
6018575 (Figure 4.2) as inducers of a self-organizing balloon-like structure (Figure 4.3A; 
hereafter referred to as “balloons”). For balloon formation, 5373471 (2.5 - 5 M) or 
6018575 (2.5 - 5 M) was first added for 5 - 6 days to induce differentiation; cells were 
then let grow freely without any further guidance (Materials and Methods). Balloons 
generally start to emerge at around day 10. A typical "balloon" consists of a closed 
spherical structure which is usually suspended in the culture medium (but sometimes 
remained adherent to the culture surface) and a stalk-like structure (“stalks” hereafter) 
which links the spherical structure to the culture surface (Figures 4.3). The spherical 
structure in a balloon is always filled with colorless fluid, and it keeps accumulating fluid 
and bulge during prolonged periods of culture. The suspended balloons gently move 
about, as driven by disturbances in the culture medium, while remaining firmly attached 
to the culture surface. I hereafter refer to compounds 5373471 and 6018575 as Lymphgen 
1 and Lymphge 2, respectively, for simplicity and consistency throughout the text. 
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Gene expression profiling and functional tests revealed an endothelial identity of the 
balloons 
To identify lineage-specificity of the balloons, I examined their gene-expression 
profile. Quantitative-PCR (qPCR) analysis showed consistent elevations of endothelial 
lineage-specific markers, including general endothelial markers VE-cadherin (Vestweber, 
2008), KDR (Samuel et al., 2013), CD31 (Kane et al., 2010), CD34 (Nakajima-Takagi et 
al., 2013), etc., and markers specific to arterial, venous, and lymphatic endothelia, in the 
balloon cultures as compared to the DMSO controls (Figures 4.4). Fluorescent-activated 
cell sorting (FACS) also showed that endothelial-specific markers VE-cadherin, CD31, 
CD34, CXCR4 (Gupta et al., 1998), UEA1 (a human endothelial cell-specific lectin) 
(Christenson and Stouffer, 1996), and KDR were elevated compared to the DMSO 
control (Figure 4.5). Only the spherical parts of the balloons (Figure 4.6, red arrows) and 
the core of the stalks (Figure 4.6, white arrows) stained positive for VE-cadherin and 
actively took up DiI-Ac-LDL (Figure 4.6), both of which characteristics of endothelial 
cells (Vestweber, 2008; Voyta et al., 1984). To rule out the existence of other lineages in 
the balloon cultures, I examined two lineages in particular that are known to be closely 
related to the endothelial lineage during development: the mural cells (including vascular 
smooth muscle cells and pericytes) (Sone et al., 2007) and the blood lineage (Kennedy et 
al., 2007). The mRNA expressions of blood lineage-specific markers, including 
hematopoietic progenitor markers and sub-lineage markers specifying lymphoid and 
myeloid identities, were not elevated compared to the DMSO control (Figure 4.7); neither 
was the mural cell-specific marker Calponin (Figure 4.7). Altogether, these results 
suggested an endothelial identity of the balloons, especially for the core parts of the 
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balloon structure, and also indicated that differentiations toward the blood lineage and to 
mural cells were not triggered in the balloon cultures.  
 
Functional Assays further confirmed the endothelial identity of the balloons. A 
selective-adhesion assay (Materials and Methods) showed that, 3 days after re-plating of 
12-day balloon cultures and a DMSO control at the same density into an endothelial-
specific culture condition, the number of adherent cells in cultures seeded by Lymphgen-
treated cells was significantly higher than in the culture seeded by the DMSO control 
(Figure 4.8A). Nearly all remaining cells took up DiI-Ac-LDL (Figure 4.8B), verifying 
the effectiveness of this selective adhesion method. A Matrigel vessel-formation assay 
(Materials and Methods), which examines the ability of cells to form vascular networks 
in vitro, also showed that only cells from the balloon cultures formed vessel networks 
(Figure 4.9).  
 
Morphological analysis gave rise to a working model of balloon self-organization 
To study the balloon-formation process, I started with the observation that 
balloon-like structures start to appear at around day 10, and then continue to emerge and 
grow for prolonged periods of time. This means that at any given time after day 10, a 
Lymphgen-induced culture should contain multiple balloon-like structures reaching 
various stages of balloon-formation. I thus examined multiple cultures at fixed time 
points after day 10 (with a focus on days 12 - 13) to reconstruct the balloon-formation 
process.   
 
129 
 
The general appearance of a culture at around days 12 to 13 is highly 
heterogeneous. Parts of the culture remain flat on the surface, with some areas 
maintaining an epithelial appearance (similar to that of a pluripotent colony) while other 
areas a mesenchymal appearance (Figure 4.10, left column). Other parts of the culture are 
elevated in the form of balloon-like structures or irregularly shaped cell aggregates 
(Figure 4.10, middle and right columns). To distinguish endothelial structures from the 
rest of the culture, I incubated live cultures with DiI-Ac-LDL to allow cells of endothelial 
identity to take up the dye before microscopic examination. I identified the following 
distinctive structures formed by DiI-Ac-LDL+ cells. First, I found clusters of DiI-Ac-
LDL+ round cells with mesenchymal characteristics that are elevated above (but remain 
attached to) the epithelial-looking cell sheet (Figure 4.10, left column; hereafter referred 
to as "clusters"). Second, I found closed spherical structures that remain directly (without 
the help of "stalks") attached to the culture surface and are much smaller in size 
compared to the suspended balloons (Figure 4.10, middle column; hereafter referred to as 
"spheres"). Most of those "spheres" seemed to have grown out of irregularly shaped DiI-
Ac-LDL+ cell aggregates (Figure 4.10, middle and right columns, white arrows) as 
judged by their proximity. Finally, as expected, I identified balloon-like structures 
(Figure 4.10, right column) as already discussed. 
  
Based on these observations I propose a working model for the balloon-
development process (Figure 4.11): DiI-Ac-LDL+ cells, which are likely to be endothelial 
progenitor cells, first emerge from the epithelial-looking cell sheets and form "clusters"; 
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the clusters then grow to form irregularly-shaped cell aggregates, from which sprout the 
"spheres"; the spheres eventually grow into balloons (Figure 4.11).  
  
Identification of a DiI-Ac-LDL+VE-cadherin+CD31+CD34+KDR+CD43- endothelial 
progenitor population during balloon formation 
To verify this model in detail, I first investigated the identity of the cells in 
"clusters". By double-staining a balloon culture using DiI-Ac-LDL and VE-cadherin, I 
found that a majority of the cells in the clusters were DiI-Ac-LDL+VE-cadherin+ (Figure 
4.12). I then further analyzed the identity of the VE-cadherin+ cells using flow cytometry, 
and found a distinct VE-cadherin+ population which typically constitutes 0.2 – 0.8% of 
the total population of a 12- to 13-day balloon culture (Figure 4.13A, top-left plot). By 
gating the VE-cadherin+ population, I found that almost all VE-cadherin+ cells were 
positive for endothelial progenitor markers KDR (95.96%) and CD31 (98.16%) (Figure 
4.13A, top row). When plotted against the side scatter channel (SSC), CD31+ cells appear 
as a distinct population as well; this population is almost entirely VE-cadherin+ (Figure 
4.13A, bottom row, 93.50%), indicating the existence of a VE-cadherin+CD31+ 
population in the balloon cultures. To further verify the endothelial identity of this 
population, I triple stained CD31 with CD34, a marker expressed in both endothelial and 
hematopoietic progenitors (Nakajima-Takagi et al., 2013), and CD43, a marker restricted 
to the hematopoietic lineage (Vodyanik et al., 2006). I found that the VE-cadherin+CD31+ 
population was CD34+, but CD43- (Figure 4.13B), thus further demonstrating an 
endothelial rather than hematopoietic identity of this population. Taken together with the 
staining result, these results demonstrate that the "clusters" contain a population of DiI-
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Ac-LDL+VE-cadherin+CD31+CD34+KDR+CD43- cells that are likely to be of an 
endothelial progenitor identity. 
 
The balloon self-organizing system recapitulates lymphatic morphogenesis in vitro 
I then compared the balloon-formation process with in vivo endothelial 
development programs including vascular- (blood vessel) and lymphatic-lineage 
specifications in order to identify the in vivo relevance of balloon morphogenesis, and 
found striking morphological similarities between balloon formation and lymphatic 
development. First, lymphatic vessels develop from sac-like structures called primitive 
lymphatic plexuses (Martinez-Corral and Makinen, 2013; Tammela and Alitalo, 2010) 
which are morphologically very similar to the "spheres" (Figure 4.10, middle column). 
Second, primitive lymphatic plexuses form by sprouting out of venous vessels, and as 
one matures, its connection with the venous vessel would constrict, fuse, and eventually 
sever (Tammela and Alitalo, 2010); this is also very similar to the balloon-formation 
process during which a balloon, although never completely detaches from the culture 
surface, separates itself from the surface by developing a stalk-like structure containing a 
core that stains positive for DiI-Ac-LDL and VE-cadherin (Figure 4.6, white arrows) but 
is completely fused and does not contain any cavities. This phenomenon, while hard to be 
explained under a blood-vessel development scenario, fits well with a lymphatic 
development model. Finally, mature balloons continue to accumulate fluid and bulge, 
similar to mature lymphatic vessels which collect interstitial fluid and produce lymph. 
These morphological similarities strongly suggest that balloon formation mimics the in 
vivo lymphatic morphogenesis.  
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I then further compared the similarities between balloon formation and lymphatic 
development on a molecular level. First, I studied resemblances between sphere 
formation and lymphatic sprouting. Based on in vivo studies showing that sprouting 
primitive lymphatic plexuses express the surface receptor VEGFR3 (Tammela and 
Alitalo, 2010), I originally hypothesized that, due to the morphological resemblance 
between spheres and primitive lymphatic plexus, the spheres may represent an in vitro 
counterpart of the primitive lymphatic plexus, and thus stain positive for VEGFR3 in toto. 
Surprisingly, in each sphere, only some of the cells stain positive for VEGFR3 while the 
rest remain VEGFR3- (Figure 4.14). Moreover, these VEGFR3+ cells are grouped 
together in each sphere in the shape of a sprout (Figure 4.14, white arrows; hereafter 
referred to as the "VEGFR3+ sprouts") which appears to be budding out of the rest of the 
sphere. I thus adjusted my original hypothesis and proposed that it is the VEGFR3+ 
sprouts, rather than the spheres in toto, that mimic primitive lymphatic plexuses. Second, 
I compared balloons with the primitive lymphatic plexuses after venous separation. While 
primitive lymphatic plexuses continue to express VEGFR3 after venous separation, the 
spherical structures of balloons are also positive for VEGFR3 in their entirety (Figure 
4.15), once again demonstrating the lymphatic identity of the balloons. This data also 
suggested that the balloons most likely originated from the VEGFR3+ sprouts rather than 
from the VEGFR3- parts of the spheres.   
  
Finally, I investigated the origin of the VEGFR3+ sprouts. I argued that the 
VEGFR3+ sprouts may have originated from VEGFR3+ progenitor cells that existed as a 
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subgroup within the DiI-Ac-LDL+VE-cadherin+CD31+CD34+KDR+CD43- endothelial 
progenitor population. Indeed, using immunofluorescence staining, I found VEGFR3+ 
cells in the DiI-Ac-LDL+VE-cadherin+CD31+CD34+KDR+CD43- progenitor clusters 
(Figure 4.16). FACS analysis also showed a VEGFR3+ population that only exists in the 
balloon cultures (Figure 4.17A, black arrow). Double staining of VEGFR3 and CD31 
followed by FACS analysis demonstrated that approximately 60% of the CD31+ cells in a 
12-day balloon culture are positive for VEGFR3 (Figure 4.17B). VEGFR3+ progenitor 
cells have been reported to be responsible for mouse embryonic lymphatic differentiation 
(Kono et al., 2006; Suzuki et al., 2005), while a VEGFR3+CD34+ progenitor population 
has been reported to be responsible for human postnatal lymphangiogenesis (Salven et al., 
2003; Tan et al., 2014). However, to date, the progenitor population responsible for 
human lymphatic development at the embryonic stage has not been identified. My data 
shows, for the first time, the possible existence of a VEGFR3+CD31+ human embryonic 
lymphatic progenitor population.  
  
I now propose an updated model of the balloon self-organization system (Figure 
4.18). In this model, Lymphgen-treatment first induces the formation of "clusters" 
containing DiI-Ac-LDL+VE-cadherin+CD31+CD34+KDR+CD43-VEGFR3- 
(Endo+VEGFR3- for short) endothelial progenitors (blue) and Endo+VEGFR3+ lymphatic 
progenitors (red). Together, these progenitors grow into "spheres" which may mimic 
venous vessels in vivo. The Endo+VEGFR3+ lymphatic progenitor cells within those 
spheres form VEGFR3+ sprouts, which then grow into "balloons" that represent primitive 
lymphatic plexuses. The connections between balloons and spheres eventually constrict, 
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giving rise to stalks which may represent a remnant structure that mimics an incomplete 
separation between a primitive lymlphatic plexus and a venous vessel. In summary, my 
data strongly suggest that this spontaneous balloon self-organizing system recapitulates 
the complicated process of lymphatic morphogenesis in vitro without any external 
guidance, thus providing a valuable system for the study of early human lymphatic 
development while proving the feasibility of establishing a completely spontaneous self-
organizing system of hESCs using small molecules as the initial stimuli. 
 
Discussion 
In this study I conducted a chemical screening designed based on a novel 
hypothesis for hESC differentiation induction, and successfully identified small 
molecules Lymphgen 1 and 2 as inducers of a spontaneous self-organizing 3-D organoid 
structure which was later demonstrated to recapitulate human lymphatic development. 
Free of growth-factor guidance, this method gives rise to the first truly spontaneous self-
organizing organogenesis system, challenges the conventional thinking in the designing 
of organoid-induction protocols, and provides novel insights into our understandings of 
self-organizing processes or emergent behavior during organogenesis. 
  
Furthermore, I successfully exploited this system to unveil the unguided 
emergence of a DiI-Ac-LDL+VE-cadherin+CD31+CD34+KDR+CD43- endothelial 
progenitor population during differentiation. I also identified a previously unknown 
VEGFR3+CD31+ progenitor population which may be responsible for human lymphatic 
development at the embryonic stage. Last but not least, this organoid-formation system 
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provides a rare opportunity to visualize the truly spontaneous progression of human 
lymphatic morphogenesis in vitro for the first time. 
  
Finally, this system provides a potential platform for the investigations of human 
diseases related to the lymphatic system, including hereditary diseases such as Milroy's 
disease (Butler et al., 2007), and many other common pathological conditions such as 
tumor migration and chronic inflammation (Schulte-Merker et al., 2011). 
 
Materials and Methods 
Cell culture 
H9 and H1 hESC lines (WiCell Research Institute, Madison, WI) were 
maintained under a feeder condition or a feeder-independent condition. For the feeder 
condition (Thomson et al., 1998), primary mouse embryonic fibroblasts (MEFs) prepared 
from embryos of pregnant CF-1 mice (day 13.5 of gestation; Charles River) were 
cultured in Dulbecco’s Modified Eagle Medium (DMEM) containing 10% FBS 
(Hyclone), 1% non-essential amino acids (NEAA; Invitrogen), and 
penicillin/streptomycin, and mitotically inactivated by gamma irradiation. H9 and H1 
hESCs were cultured on irradiated MEFs in media containing DMEM/F12, 20% 
knockout serum replacement (KSR; Invitrogen), 4 ng/ml basic fibroblast growth factor 
(bFGF; Invitrogen), 1% NEAA, 1 mM glutamine, and 0.1 mM β-mercaptoethanol. For 
the feeder-independent condition, hESCs were cultured on Matrigel (BD Biosciences)-
coated plates in mTeSR1 medium (StemCell Technologies) as described (Ludwig et al., 
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2006). Experiments described in this study were conducted with H9 and H1 hESCs 
between passages 30 and 60.  
 
Morphological screen 
For the morphological screen, H9 and H1 hESCs were plated in Matrigel coated 
vessels as 2-D cultures in a basal medium composed of RPMI-1640 medium and 2% B-
27 supplement (Invitrogen). Small molecules were individually applied to each culture, 
and incubated for 5 to 6 days before withdrawn. Cultures were then kept in the basal 
medium alone, without the addition of any growth factors, and let grown for 6 days or 
longer. During this prolonged incubation period, cultures were examined regularly for the 
emergence of 3-D organoid-like structures. 
 
Balloon culture 
H9 and H1 hESCs cultured on MEF feeders or Matrigel were dissociated by brief 
exposure to type IV collagenase (1 mg/ml; Invitrogen) or Dispase (Invitrogen), 
respectively, followed by mechanical dissociation into cell clumps. It is crucial to plate 
cells in clumps rather than single cells for the balloon formation. Cell clumps were 
seeded into Matrigel coated vessels in mTeSR1 medium at high density: generally at a 
1:2 passaging ratio for MEF-cultured cells, and 1:1 for Matrigel-cultured cells. Cultures 
were then maintained in mTeSR1 medium with daily medium change until reaching 
approximately 90% confluency. Culture medium were then switched to a basal 
differentiation medium containing Advanced RPMI 1640 (Invitrogen), 2% B-27 
supplement (Invitrogen), and 1% Glutamax (Invitrogen). Medium was changed every 
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other day. Lymphgen 1 and 2 were applied to the culture at 2.5 - 5 M for the first 6 days. 
Balloons typically emerge at around day 10. 
 
Selective adhesion assay 
Cells from balloon cultures and DMSO control were trypsinized into single cells, 
counted using a hematocytometer, and seeded into Fibronectin (BD Biosciences) coated 
culture vessels in endothelial culture medium (ATCC) at a density of 1.5 × 104 cells/cm2. 
Numbers of adherent cells and their endothelial identities were examined 3 days after 
seeding.  
 
Matrigel assay 
Cells from balloon cultures and DMSO control were trypsinized into single cells, 
counted using a hematocytometer, and encapsulated in Matrigel (kept cool to prevent 
gelation) at 1.0 × 106 cells/ml. Cultures were then kept in 37°C for 1 hour to allow 
formation of solid gels. Endothelial culture medium (ATCC) was added to each well. 
Medium was changed every other day. The emergences of vessel-like networks were 
monitored, and images were acquired using microscopy (Zeiss). 
 
DiI-Ac-LDL staining 
DiI-Ac-LDL were added to live cell culture at a 1:20 dilution and incubated at 
37°C for 4 hr. Medium was then removed, and cells were washed with cell culture 
medium and visualized via fluorescent microscopy (Zeiss). 
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RNA extraction, reverse transcription, and quantitative-PCR 
Total RNA were isolated using RNeasy mini kit (QIAGEN). cDNAs were 
synthesized from the purified RNAs using Reverse Transcription System (Promega). 
Quantitative-PCR was performed using QuantiTech SYBR Green PCR kit (QIAGEN). 
Signals were analyzed using the comparative CT method, and ACTB gene was used as an 
internal control.  
 
Flow cytometry  
Single cell suspensions were acquired through Accutase (Invitrogen) treatment. 
Cells were stained using conjugated or unconjugated antibodies or UEA1 lectin for 30 
min on ice. Cells stained by unconjugated antibodies were washed by ice cold FACS 
buffer (PBS supplemented with 1% BSA) and then stained using fluorescent-conjugated 
secondary antibodies for an extra 30 min. Cells were then washed and resuspended in ice 
cold FACS buffer and analyzed using a BD Biosciences LSR II flow cytometry analyzer 
and BD FACSDiva software.  
 
Immunofluorescent staining 
Cells were washed once with phosphate-buffered saline (PBS) and fixed by 4% 
paraformaldahyde (Santa Cruz) at room temperature for 15 min and then blocked with 5% 
donkey serum (Sigma) in PBS at room temperature for 1 hr. The samples were incubated 
with primary antibodies in PBST (PBS supplemented with 1% Triton) at 4°C overnight, 
washed three times by PBS, and then incubated with fluorescent-labeled secondary 
antibodies in PBST at room temperature for 1 hr. Finally, cells were incubated with DAPI 
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for 5 min, washed three times by PBS, and subjected to fluorescent microscopy analysis 
(Zeiss). 
 
Statistical analysis 
Statistical analyses were performed using Microsoft Excel. Student’s t-test was 
used to compare two experimental groups, assuming unequal variances.  Differences are 
considered significant when p < 0.05. 
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Tables 
Antibody Source Catalog 
Number 
Dilution 
VE-cadherin R&D Systems AF938 1:500 (IF) / 1:50 (FACS) 
VEGFR3 Millipore MAB3757 1:50 (IF) / 1:50 (FACS) 
CD31-PE BD 
Biosciences 
560983 1:5 (FACS) 
CD31-FITC BD 
Biosciences 
555445 1:5 (FACS) 
VE-cadherin-Alexa647 BD 
Biosciences 
561567 1:20 (FACS) 
KDR-PE BD 
Biosciences 
560494 1:5 (FACS) 
CD34-APC BD 
Biosciences 
560940 1:5 (FACS) 
CD43-FITC BD 
Biosciences 
560978 1:5 (FACS) 
CXCR4 R&D Systems MAB172 1:1000 (FACS) 
CD34 Millipore CBL496 1:50 (FACS) 
KDR Millipore 05-554 1:50 (FACS) 
Donkey anti-mouse, Alexa 
488 
Invitrogen A-21202 1:200 (FACS) 
Donkey anti-goat, Alexa 
488 
Invitrogen A-11055 1:200 (FACS) 
Donkey anti-mouse, Alexa 
594 
Invitrogen A-21203 1:200 (FACS) 
UEA1-Fluorescein Vector Labs FL-1061 1:1000 (FACS) 
DiI-Ac-LDL Biomedical 
Technologies 
BT-902 1:20 (IF) 
Phalloidin, Alexa 488 Invitrogen A12379 1:1000 (IF) 
 (IF: immunofluorescence) 
 
Table 4.1. Antibodies and fluorescent dyes 
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Primer Name Forward Primer (5'-3') Reverse Primer (5'-3') 
ACTB agagctacgagctgcctgac cgtggatgccacaggact 
VE-cadherin gttcacgcatcggttgttcaa cgcttccaccacgatctcata 
VEGFR1 (FLT1) gtcacagaagaggatgaaggtgtc cacagtccggcacgtaggtgatt 
VEGFR2 (KDR) tttttgcccttgttctgtcc tcattgttcccagcatttca 
VEGFR3 (FLT4) agacaagaaagcggcttcag cctcccttgggagtcagg 
PDGFRA ccacctgagtgagattgtgg tcttcaggaagtccaggtgaa 
CD31 (PECAM1) tctatgacctcgccctccacaaa gaacggtgtcttcaggttggtatttca 
CD34 gcgctttgcttgctgagt gggtagcagtaccgttgttgt 
TIE1 agaacctagcctccaagatt actgtagttcagggactcaa 
TIE2 tccaaggatgtctctgctctc ttggggtcatcctcggtat 
CD105 (Endoglin) ttcctggagttcccaacg aggtgccattttgcttgg 
EphB4 cgcacctacgaagtgtgtga gtccgcatcgctctcatagta 
Ephrin-B2 tatgcagaactgcgatttccaa tgggtatagtaccagtccttgtc 
vWF agtgcagacccaacttcacc gtggggacactcttttgcac 
Thrombomodulin aattgggagcttgggaatg tgaggacctgattaaggctagg 
E-selectin accagcccaggttgaatg ggttggacaaggctgtgc 
PROX1 gagcctccgtggaactca tgggcacagctcaagaatc 
Podoplanin aaatgtcgggaaggtactcg agggcacagagtcagaaacg 
FLT3 tggaatttctggaatttaagtcg tttcccgtgggtgacaag 
PROM1 tccacagaaatttacctacattgg cagcagagagcagatgacca 
PROM2 tgcagctcaacgactcctac actcctgccgtagcttgttg 
THY1 aggacgagggcacctacac gccctcacacttgaccagtt 
CCR1 tctgactcttggcacagcat gccaccattacattccctctc 
CD44 caacaacacaaatggctggt ctgaggtgtctgtctctttcatct 
CD45 ccaatgcaaaactcaacccta cctctctcctgggacatctg 
TAL1 accctagccctctccctcta ggccacaggctatctctcct 
NFE2 gggagcctcatctctctcct agcccagatggctctagaaa 
SPI1 caggggatctgaccgactc aggtcttctgatggctgagg 
c-kit aagagatgtgactcccgccat aggaaagccatgccctttg 
GATA2 aaggctcgttcctgttcaga ggcattgcacaggtagtgg 
RUNX1 ccctaggggatgttccagat tgaagcttttccctcttcca 
CD38 cagcaacaaccctgtttcagt ccattgagcatcacatggac 
VAV1 agcagacggaggagaagtaca caggggcttcaagaaatgc 
CD79A caagaaccgaatcatcacagc cgttctgccatcgtttcc 
CD3E caaggccaagcctgtgac tcatagtctgggttgggaaca 
PTCRA ccagccctacccacaggt atcaaggaccaggcagacc 
CCR5 aaccaggcgagagacttgtg gatccaactcaaattccttctca 
IL3RA tcccgatggtcctccttt tgattggtgggtttggatct 
 
Table 4.2. qPCR primers 
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Table 4.2. (Cont.) 
ANPEP catccatcagagatggcagac tgctgaagagatcgttctgg 
CD33 caggaatgacacccacccta tcagtggggccatgtaactt 
LMO2 ttcaacctgaacttgcagtagc gcttccctctgtctctggttt 
GATA1 cactgagcttgccacatcc atggagcctctggggatta 
EMR1 gccagtttgcacagttatagtga  gacttcggcattaacactgga 
ITGAM ggcatccgcaaagtggta ggatcttaaaggcattctttcg 
Calponin1 ctgtcagccgaggttaagaac gaggccgtccatgaagttgtt 
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